"acute coronary syndrome" AND "management guidelines"

"acute coronary syndrome" AND guidelines

ls /home/daytona/workspace/ 2>/dev/null && echo "---" && which weasyprint wkhtml…

python3 -c "import reportlab; print('reportlab ok')" 2>/dev/null; python3 -c "fr…

mkdir -p /home/daytona/workspace/hkmle-acs && echo "dir ready"

~/hkmle-acs/ACS_HKMLE_Notes.md

# HKMLE MODULE 1A: ACUTE CORONARY SYNDROME
### Complete High-Yield Study Note | HKMLE-Ready

---

## DETAILED TABLE OF CONTENTS

| # | Section |
|---|---------|
| 1 | ACS Overview & Spectrum |
| 2 | Pathophysiology of Plaque Rupture |
| 3 | Stable Angina |
| 4 | Unstable Angina (UA) |
| 5 | NSTEMI |
| 6 | STEMI |
| 7 | ECG Interpretation in ACS |
| 8 | Cardiac Biomarkers |
| 9 | Risk Stratification (TIMI, GRACE) |
| 10 | ACS Management Overview & DAPT |
| 11 | Reperfusion Strategy (PCI vs Thrombolysis) |
| 12 | Long-Term Secondary Prevention |
| 13 | Post-MI Complications Overview |
| 14 | VSD Post-MI |
| 15 | Mitral Regurgitation Post-MI |
| 16 | LV Free Wall Rupture |
| 17 | Early Pericarditis Post-MI |
| 18 | Dressler's Syndrome |
| 19 | LV Aneurysm |
| 20 | Mural Thrombus |
| 21 | Drug Traps Table |
| 22 | Notable Trials Table |
| 23 | Master Mnemonics Table |
| 24 | Cross-Module Links |

---

\newpage

# PAGE 1: ACS OVERVIEW & SPECTRUM

## Definition

**Acute Coronary Syndrome (ACS)** is an umbrella term for the continuum of myocardial ischaemia and infarction resulting from acute reduction in coronary blood flow. It encompasses stable angina, unstable angina (UA), non-ST elevation MI (NSTEMI), and ST elevation MI (STEMI).

> "ACS = the patient with chest pain whose coronary blood supply is acutely threatened."

---

## The ACS Spectrum

| Feature | Stable Angina | Unstable Angina | NSTEMI | STEMI |
|---|---|---|---|---|
| **Troponin** | Normal | Normal | **Elevated** | **Elevated** |
| **ST changes** | Transient on stress | Depression/T-inversion at rest | Depression/T-inversion | **Persistent elevation >20 min** |
| **Plaque** | Fixed stenosis | Partial rupture | Partial rupture/subtotal | **Complete occlusion** |
| **Necrosis** | None | None | Yes (subendocardial) | Yes (transmural) |
| **Urgency** | Elective | Urgent (24-48h) | Urgent | **EMERGENCY** |

---

## Universal MI Type Classification

| Type | Mechanism |
|---|---|
| **Type 1** | Spontaneous atherothrombosis (plaque rupture/erosion) |
| **Type 2** | Supply-demand mismatch (anaemia, tachycardia, hypotension, cocaine) |
| **Type 3** | Sudden death without biomarker/ECG confirmation |
| **Type 4a** | PCI-related MI |
| **Type 4b** | In-stent thrombosis |
| **Type 5** | CABG-related MI |

> **QUICK SUMMARY:** Type 2 MI = treat the underlying cause, NOT with thrombolytics.

---

## BASIC SCIENCE: Coronary Artery Territory

| Artery | Territory | ECG Leads |
|---|---|---|
| **LAD** | Anterior LV, anterior septum, apex | V1-V4 |
| **RCA** | Inferior LV, posterior wall, SA/AV nodes, RV | II, III, aVF |
| **LCx** | Lateral LV, posterior wall | I, aVL, V5-V6 |
| **PDA** | Posterior wall | Reciprocal V1-V2 |

> **RCA occlusion = inferior MI = bradycardia/heart block**
> **LAD occlusion = anterior MI = worst prognosis, cardiogenic shock risk**

---

\newpage

# PAGE 2: PATHOPHYSIOLOGY OF PLAQUE RUPTURE

## Step-by-Step Pathophysiology

**STEP 1 - ATHEROSCLEROSIS DEVELOPS**

- Endothelial injury (HTN, smoking, DM, hyperlipidaemia)
- LDL enters intima → oxidised → foam cells (macrophages eating ox-LDL)
- Fatty streak → fibrous plaque → vulnerable plaque

**STEP 2 - VULNERABLE PLAQUE STRUCTURE**

- Large lipid core, thin fibrous cap, high macrophage content
- NOTE: Vulnerable plaques may NOT cause significant stenosis → stress test may be NORMAL before MI!

**STEP 3 - PLAQUE RUPTURE / EROSION**

- Trigger: physical exertion, emotion, cold, sympathetic surge
- Mechanical stress on thin cap → RUPTURE → lipid core exposed to blood (highly thrombogenic)

**STEP 4 - PLATELET ACTIVATION**

- vWF + collagen bind platelet GpIb → ADP, TXA2 release → GpIIb/IIIa activated → fibrinogen bridges → WHITE THROMBUS

**STEP 5 - COAGULATION CASCADE**

- Tissue factor → extrinsic pathway → thrombin → fibrin → RED THROMBUS

**STEP 6 - CORONARY OCCLUSION**

- SUBTOTAL → UA / NSTEMI
- TOTAL → STEMI

**STEP 7 - ISCHAEMIA → INJURY → INFARCTION**

- Anaerobic metabolism → K+ leaks out (arrhythmia risk!) → Ca2+ overload → necrosis after ~20-40 min

---

## Infarct Evolution Timeline

| Time | Gross Pathology | Histology | Clinical Significance |
|---|---|---|---|
| 0-6h | None visible | Coagulative necrosis begins | Peak VF risk |
| 6-24h | Pallor | Neutrophil infiltration | Rupture begins to be possible |
| 1-3 days | Yellow pallor | Neutrophil peak | Rupture risk low |
| **3-7 days** | **Softening, yellow centre** | **Macrophage infiltration** | **PEAK RUPTURE RISK** |
| 1-2 weeks | Granulation tissue | Fibroblasts, new vessels | Early scar |
| 6+ weeks | White scar | Dense collagen | Completed scar |

> **HKMLE TRAP:** Free wall rupture, VSD, and papillary muscle rupture most commonly occur **3-7 days** post-MI. The HKMLE loves to test this timing!

---

## Risk Factors - Mnemonic: "SAD FISHES"

**Modifiable:** Smoking, Hypertension, Diabetes mellitus, Hyperlipidaemia, Obesity, Sedentary lifestyle, CKD, Rheumatoid arthritis

**Non-Modifiable:** Age (M >45, F >55), Sex (M > F; post-menopausal women = higher risk), Family history (1st degree relative <55M or <65F)

---

\newpage

# PAGE 3: STABLE ANGINA

## Definition

Stable angina is **episodic chest discomfort** caused by **transient myocardial ischaemia** from a fixed coronary stenosis (>70%), occurring predictably with exertion and relieved by rest or GTN within 1-5 minutes. There is **no myocyte necrosis** and **no troponin rise**.

---

## Aetiology - Mnemonic: "CASH BAD"

- **C**oronary artery disease (most common)
- **A**ortic stenosis
- **S**pasmodic coronary vasospasm (Prinzmetal)
- **H**ypertrophic cardiomyopathy
- **B**ridging of myocardium
- **A**naemia (supply-demand mismatch)
- **D**ysfunctional endothelium / microvascular disease

---

## CCS (Canadian Cardiovascular Society) Classification

| Class | Description |
|---|---|
| **I** | Angina only with strenuous exertion; no limitation of ordinary activity |
| **II** | Slight limitation; angina on brisk walking, stairs, after meals |
| **III** | Marked limitation; angina walking 1-2 blocks on level, 1 flight stairs |
| **IV** | Angina at rest or any physical activity |

---

## Symptoms - Mnemonic: "SCOTLAND"

| Feature | Details |
|---|---|
| **S**ite | Central/retrosternal |
| **C**haracter | Pressure, squeezing, heaviness (NOT sharp or stabbing) |
| **O**nset | Exertional (exercise, cold, emotion, sex, heavy meal) |
| **T**iming | Crescendo-decrescendo, lasts 2-5 minutes |
| **L**evine's Sign | Clenched fist over sternum |
| **A**lleviating | Rest + GTN within 1-5 minutes |
| **N**ot | Does NOT radiate to trapezius (that's pericarditis!) |
| **D**irection | Radiates: left arm (ulnar), jaw, teeth, back, epigastrium |

> **HKMLE TRAP:** Angina does NOT radiate to the trapezius. Trapezius radiation = pericarditis!

---

## Investigations - Mnemonic: "BEAST ECG"

| Investigation | Finding |
|---|---|
| **B**loods (FBC, lipids, glucose, TFT, renal) | Risk factors |
| **E**CG (resting) | Often normal; may show old Q waves |
| **A**mbulatory ECG (Holter) | Dynamic ST changes |
| **S**tress ECG (ETT) | ST depression ≥1mm at peak |
| **T**hallium / Nuclear MPI | Perfusion defect |
| **E**cho (stress echo) | Wall motion abnormality on stress |
| **C**T Coronary Angiography (CTCA) | Non-invasive; rule out significant stenosis |
| **G**old standard: Invasive Coronary Angiography | Define anatomy, plan PCI/CABG |

> **HKMLE TRAP:** ETT is contraindicated if resting ECG shows LBBB, WPW, or significant ST depression. Use imaging modality (stress echo or nuclear) instead!

---

## Management - Mnemonic: "ABBA SN"

| Drug | Mechanism | Note |
|---|---|---|
| **A**spirin 75mg daily | Antiplatelet | All patients |
| **B**eta-blocker (bisoprolol, metoprolol) | Decrease HR + contractility → decrease O2 demand | 1st line anti-anginal |
| **B**eta-blocker alternative: CCB (amlodipine) | Vasodilation | If BB contraindicated |
| **A**CE inhibitor | Cardioprotective | If DM, CKD, HF, HTN |
| **S**tatin (atorvastatin 40-80mg) | Lipid lowering | Target LDL <1.8 mmol/L |
| **N**itrates (GTN spray, isosorbide mononitrate) | Venodilation → decrease preload | GTN prn; always use nitrate-free window 8-12h |

### Revascularisation

| Indication | Preferred |
|---|---|
| Single or double vessel disease | PCI |
| Triple vessel disease + normal LV / low SYNTAX | PCI or CABG |
| Triple vessel disease + DM | **CABG preferred** (FREEDOM trial) |
| Left main stem disease | CABG preferred |

---

\newpage

# PAGE 4: UNSTABLE ANGINA (UA)

## Definition

Unstable angina is **chest pain at rest, new-onset angina, or rapidly worsening (crescendo) angina**, WITHOUT elevation of cardiac biomarkers (troponin is **NORMAL**).

## The 3 Presentations

1. **Rest angina** - occurring at rest, lasting >20 minutes
2. **New-onset angina** - new angina at least CCS III severity
3. **Crescendo angina** - previously stable, now more frequent/prolonged/severe (CCS III or worse)

---

## Aetiology - Mnemonic: "SCRAPS"

- **S**pontaneous plaque rupture/erosion (most common)
- **C**ocaine / sympathomimetics
- **R**apid demand increase (tachyarrhythmia, thyrotoxicosis)
- **A**naemia
- **P**erinatal (spontaneous coronary dissection)
- **S**pasmodic (Prinzmetal)

---

## Pathophysiology

Vulnerable plaque → **partial rupture** → partial (non-occlusive) thrombus → subtotal obstruction → intermittent ischaemia → **NO sustained necrosis → troponin NORMAL** → can progress to NSTEMI or STEMI at any moment.

---

## RED FLAGS in UA

- Pain at rest >20 minutes
- Haemodynamic instability (hypotension, new MR murmur)
- Signs of acute pulmonary oedema
- New ST depression >2mm
- ST elevation >20 min (= STEMI - treat accordingly!)
- Positive troponin (= NSTEMI, not UA)

---

\newpage

# PAGE 5: NSTEMI

## Definition

NSTEMI is **myocardial ischaemia with myocyte necrosis** (elevated troponin), WITHOUT persistent ST-segment elevation. Mechanism: subtotal coronary occlusion → subendocardial (non-transmural) infarction.

> UA vs NSTEMI: Identical presentation. The ONLY distinction is **TROPONIN** - elevated in NSTEMI, normal in UA.

---

## ECG Changes in NSTEMI

| Finding | Interpretation |
|---|---|
| ST depression ≥0.5mm | Subendocardial ischaemia |
| T-wave inversion (deep, symmetric) | Ischaemia in that territory |
| Dynamic changes | Strongly suggests ACS |
| Diffuse ST depression + ST elevation in aVR | **Left main stem or proximal LAD occlusion** |
| ST depression V1-V2 + tall R waves | **Posterior MI** - check V7-V9! |

> **HKMLE TRAP:** ST elevation in aVR with diffuse ST depression = LEFT MAIN STEM occlusion. This is a STEMI-equivalent requiring URGENT coronary angiography!

---

## TIMI Risk Score for UA/NSTEMI (7 points)

| Criterion | Points |
|---|---|
| Age ≥65 years | 1 |
| ≥3 CAD risk factors | 1 |
| Prior coronary stenosis ≥50% | 1 |
| ST deviation on ECG | 1 |
| ≥2 anginal events in <24h | 1 |
| Aspirin use in last 7 days | 1 |
| Elevated cardiac markers | 1 |

| Score | Risk | Strategy |
|---|---|---|
| 0-1 | Low (~5%) | Medical management |
| 2-3 | Low-intermediate (~8-13%) | Consider early invasive |
| 4-5 | Intermediate-high (~20-26%) | Early invasive (<24h) |
| 6-7 | High (~41%) | Urgent invasive (<2h) |

---

## GRACE Score

| GRACE Score | In-hospital Mortality | Strategy |
|---|---|---|
| <109 | <1% (low) | Conservative |
| 109-140 | 1-3% (intermediate) | Early invasive (24-72h) |
| >140 | >3% (high) | Very early invasive (<24h) |

> **ESC 2023 recommends GRACE score** for NSTEMI risk stratification.

---

\newpage

# PAGE 6: STEMI

## Definition

STEMI is **transmural myocardial infarction** due to **complete, persistent occlusion** of a coronary artery, characterised by:

- Persistent ST elevation >20 minutes
- Elevated troponin
- Eventual Q waves (if not revascularised early)

---

## STEMI Territory Table

| Location | ECG Leads with ST Elevation | Culprit Artery |
|---|---|---|
| **Anterior** | V1-V4 | LAD |
| **Anterolateral** | V1-V6, I, aVL | Proximal LAD |
| **Lateral** | I, aVL, V5-V6 | LCx |
| **Inferior** | II, III, aVF | RCA (80%) or LCx (20%) |
| **Posterior** | ST depression V1-V2 + tall R | PDA |
| **Right ventricular** | ST elevation V4R | Proximal RCA |

---

## ST Elevation Criteria

- Limb leads: ≥1mm (≥0.1mV)
- V2-V3: ≥2mm men (≥2.5mm if age <40), ≥1.5mm women
- V1, V4-V6: ≥1mm

> **HKMLE TRAP:** New **LBBB** with acute chest pain = STEMI equivalent. Use **Sgarbossa criteria:**
> - Concordant ST elevation ≥1mm in leads with positive QRS (3 points)
> - Concordant ST depression ≥1mm in V1-V3 (3 points)
> - Discordant ST elevation ≥5mm (2 points)
> - Score ≥3 = high probability of MI

---

## ECG Evolution of STEMI

```
Minutes:   Hyperacute T waves (tall, peaked)
Hours:     ST elevation (tombstone pattern in severe cases)
Hours-Days: Q waves develop (>0.04s wide, >25% R wave height)
Days:      T wave inversion
Weeks:     ST normalises, T may remain inverted
Permanent: Q waves persist (scar)
```

---

## Killip Classification (STEMI Severity)

| Class | Clinical Feature | 30-day Mortality |
|---|---|---|
| **I** | No heart failure | ~6% |
| **II** | S3, crackles <50% lung fields | ~17% |
| **III** | Pulmonary oedema (crackles >50%) | ~38% |
| **IV** | Cardiogenic shock (BP <90, oliguria) | ~67% |

---

## Clinical Features - Mnemonic: "SAD DAVSD"

- **S**evere crushing chest pain (>20 min, not relieved by GTN)
- **A**utonomic symptoms (sweating, nausea, vomiting)
- **D**yspnoea
- **D**izziness / presyncope
- **A**rm/jaw radiation
- **V**omiting
- **S**ilent MI (elderly, diabetics, women - atypical!)
- **D**eath (sudden, from VF in first hour)

---

\newpage

# PAGE 7: ECG INTERPRETATION IN ACS

## ECG Systematic Approach - Mnemonic: "RSVP AQRS"

**Rate:** Sinus bradycardia → inferior MI (RCA, vagotonia); VF/VT → ischaemia

**PR interval:**

| Finding | Significance |
|---|---|
| Prolonged (1st degree HB) | Inferior MI |
| Progressive PR lengthening (Mobitz I / Wenckebach) | Inferior MI |
| Fixed PR drop-out (Mobitz II) | **Anterior MI - POOR prognosis, needs pacing** |
| Complete dissociation (3rd degree HB) | Inferior MI: escape >40bpm; Anterior MI: escape <40bpm |

**QRS:**

- Q waves >40ms wide, >25% R amplitude = pathological (infarction)
- New LBBB = STEMI equivalent
- RBBB + left axis = bifascicular block (anterior MI)

---

## Pericarditis vs STEMI: Key ECG Differences

| Feature | Pericarditis | STEMI |
|---|---|---|
| ST shape | Concave (saddle-shaped) | Convex (tombstone) |
| Distribution | **Diffuse** (all leads except aVR, V1) | **Territorial** (specific territory) |
| PR segment | **PR depression** | Normal PR |
| Q waves | ABSENT | Develop over hours |
| Reciprocal changes | ABSENT | **PRESENT** |

---

\newpage

# PAGE 8: CARDIAC BIOMARKERS

## Biomarker Timeline Table

| Marker | Rises | Peaks | Returns to Normal | Key Features |
|---|---|---|---|---|
| **Troponin I/T** | 3-6h | 12-24h | 5-14 days | Most sensitive + specific; gold standard |
| **CK-MB** | 3-6h | 12-24h | 48-72h | Used to detect **reinfarction** |
| **Myoglobin** | 1-3h | 6-9h | 24h | First to rise; poor specificity |
| **LDH** | 12-24h | 3-6 days | 8-14 days | Historical use for late MI |
| **hs-Troponin** | <3h | - | - | Allows 0h/1h rapid protocol |

---

## hs-Troponin 0h/1h ESC Rapid Rule-In/Rule-Out Protocol

- hs-TnT at 0h **very LOW** (<5 ng/L) AND 0h-1h change <4 ng/L → **RULE OUT MI** (>99% NPV)
- hs-TnT **very HIGH** (>52 ng/L) OR 0h-1h change ≥6 ng/L → **RULE IN MI**
- Intermediate → 3h serial troponin + clinical assessment

---

## Causes of Troponin Elevation Other Than ACS - Mnemonic: "HEART FAILURE MAPS"

**H**F (acute decompensated), **E**ndocarditis/myocarditis/pericarditis, **A**rrhythmias (cardioversion, sustained tachycardia), **R**ight heart strain (PE, pulmonary HTN), **T**akotsubo

**F**ailure (renal - impaired clearance), **A**naemia + tachycardia (type 2 MI), **I**schaemic stroke (neurogenic), **L**ightning/electrical injury, **U**ndergoing cardiac surgery

**R**habdomyolysis, **E**ndurance exercise, **M**yocarditis, **A**ortic dissection (involves coronary os), **P**neumonitis/critical illness, **S**epsis

> **HKMLE TRAP:** A troponin rise alone does NOT diagnose ACS. The clinical context, symptoms, ECG, and KINETICS (rising vs stable/falling) are all essential.

---

\newpage

# PAGE 9: RISK STRATIFICATION

## High-Risk Features Warranting IMMEDIATE Invasive Strategy (<2h) - Mnemonic: "SHOCK STAR"

- **S**hock (haemodynamic instability)
- **H**eart failure (acute pulmonary oedema, Killip ≥III)
- **O**ngoing ischaemia (refractory chest pain despite treatment)
- **C**omplete heart block or life-threatening arrhythmia
- **K**atastrophic mechanical complication
- **S**T elevation in aVR with diffuse depression (LMS equivalent)
- **T**roponin very high and rising rapidly
- **A**rterial hypotension (SBP <90)
- **R**ecurrent ECG changes

> ESC 2023: High-risk NSTEMI → **<24h invasive**; Very high-risk → **<2h invasive**

---

## Invasive Strategy Timing Summary

| Strategy | When to Use |
|---|---|
| **Invasive (<2h)** | Any very high-risk feature (SHOCK STAR) |
| **Early invasive (<24h)** | GRACE >140, TIMI ≥5, significant ST depression |
| **Invasive (<72h)** | GRACE 109-140, TIMI 3-4, recurrent symptoms |
| **Conservative** | Low GRACE, low TIMI, no high-risk features |

---

\newpage

# PAGE 10: ACS MANAGEMENT OVERVIEW & DAPT

## Acute ACS Management - Mnemonic: "BATMAN"

| Letter | Drug / Action |
|---|---|
| **B** | Beta-blocker (oral, if no shock/bradycardia/acute HF) |
| **A** | Aspirin 300mg loading, then 75mg daily |
| **T** | Thienopyridine/P2Y12 inhibitor (ticagrelor 180mg or clopidogrel 300-600mg) |
| **M** | Morphine (CAUTION - see trap below) |
| **A** | Anticoagulation (UFH, LMWH/enoxaparin, fondaparinux, or bivalirudin) |
| **N** | Nitrate (GTN sublingual/IV for ongoing pain) |

> **HKMLE TRAP - MORPHINE:** AVOID routinely in ACS! Morphine reduces absorption of oral antiplatelet agents → worse outcomes (CRUSADE registry). Reserve for truly refractory pain only. This is a MAJOR exam trap!

> **HKMLE TRAP - OXYGEN:** Only give supplemental O2 if SpO2 <94%. Hyperoxia in normoxic ACS patients is HARMFUL. Do NOT give O2 routinely!

> **HKMLE TRAP - GTN CONTRAINDICATIONS:** GTN is CONTRAINDICATED in (1) Hypotension (SBP <90mmHg), (2) Right ventricular infarction, (3) PDE-5 inhibitor use within 24-48h (sildenafil/tadalafil).

---

## Dual Antiplatelet Therapy (DAPT) Comparison

| P2Y12 Inhibitor | Loading | Maintenance | Key Points |
|---|---|---|---|
| **Ticagrelor** | 180mg | 90mg BD | Preferred in ACS; reversible; causes dyspnoea (10%) |
| **Prasugrel** | 60mg | 10mg OD | More potent; AVOID if prior stroke/TIA, age >75, weight <60kg |
| **Clopidogrel** | 300-600mg | 75mg OD | Prodrug (CYP2C19); use if ticagrelor/prasugrel contraindicated |

**DAPT Duration:**

- After PCI for ACS: **12 months minimum**
- After bare metal stent: minimum 1 month
- After drug-eluting stent: minimum 6-12 months

> **HKMLE TRAP - CLOPIDOGREL + PPI:** Clopidogrel is a PRODRUG requiring CYP2C19 activation. Omeprazole inhibits CYP2C19 → reduces clopidogrel efficacy. Use **pantoprazole** if PPI needed!

---

## Anticoagulation in ACS

| Drug | Mechanism | Use |
|---|---|---|
| **Enoxaparin (LMWH)** | Xa + IIa inhibition | NSTEMI/UA preferred |
| **Fondaparinux** | Xa inhibition only | NSTEMI/UA with high bleeding risk |
| **UFH** | Xa + IIa | STEMI; easy to reverse with protamine |
| **Bivalirudin** | Direct thrombin inhibitor | PCI when HIT risk |

> **HKMLE TRAP:** Fondaparinux CANNOT be used as sole anticoagulant for PCI (catheter thrombosis risk). Add UFH bolus at time of PCI.

---

\newpage

# PAGE 11: REPERFUSION STRATEGY (PCI vs THROMBOLYSIS)

## Primary PCI (pPCI) - Gold Standard for STEMI

**Targets:**

- **FMC-to-balloon**: <90 min (presenting to PCI centre)
- **FMC-to-balloon**: <120 min total (if transfer needed)
- If pPCI unavailable within 120 min → give thrombolysis first (within 10 min of diagnosis)

---

## Thrombolysis (Fibrinolysis)

**Agents:**

| Drug | Type | Dose | Notes |
|---|---|---|---|
| **Alteplase (tPA)** | Fibrin-specific | 15mg bolus then infusion | Standard |
| **Tenecteplase (TNK)** | Fibrin-specific | Single weight-based bolus | Convenient |
| **Streptokinase** | Non-fibrin-specific | 1.5MU over 60min | AVOID if used in past 5 years! |

**Absolute Contraindications - Mnemonic: "HBAS-NO":**

- **H**aemorrhagic stroke (ever) or ischaemic stroke <3 months
- **B**leeding diathesis (active internal bleeding)
- **A**ortic dissection (suspected)
- **S**evere uncontrolled HTN (SBP >180)
- **N**eurosurgery / head trauma within 3 months
- **O**ngoing internal bleeding

---

## Signs of Successful Reperfusion - Mnemonic: "STAR"

- **S**T resolution >50% within 90 minutes
- **T**roponin early peak (washout from opened vessel)
- **A**IVR (accelerated idioventricular rhythm) - reperfusion arrhythmia
- **R**elief of chest pain

> **HKMLE TRAP:** Accelerated idioventricular rhythm (AIVR, rate 60-120 bpm) after thrombolysis is a **BENIGN REPERFUSION ARRHYTHMIA** - it does NOT require treatment. It is a sign of success!

---

## Rescue PCI

If thrombolysis FAILS (no ST resolution >50% at 60-90 min) → Urgent transfer for **rescue PCI**.
Do NOT repeat thrombolysis.

---

\newpage

# PAGE 12: LONG-TERM SECONDARY PREVENTION

## Post-MI Secondary Prevention - Mnemonic: "ABCDE Post-MI"

| Letter | Intervention |
|---|---|
| **A** | **Aspirin** 75mg lifelong + **ACE inhibitor** (or ARB) lifelong, especially if EF <40% |
| **B** | **Beta-blocker** lifelong (reduces mortality, especially if reduced EF) |
| **C** | **Cholesterol** - high-intensity statin (atorvastatin 40-80mg); target LDL <1.4mmol/L (ESC) |
| **D** | **DAPT** 12 months; **Diabetes** control; **Diet** (Mediterranean) |
| **E** | **Exercise** (cardiac rehabilitation); **Eplerenone** if EF <35% + HF/DM; **Ezetimibe** if LDL not at target |

---

## New Secondary Prevention Therapies

| Drug | Class | Trial | Benefit |
|---|---|---|---|
| **Ticagrelor** | P2Y12 inhibitor | PLATO | Superior to clopidogrel in ACS (all-cause mortality reduced) |
| **Prasugrel** | P2Y12 inhibitor | TRITON-TIMI 38 | Superior to clopidogrel in STEMI (more bleeding) |
| **Evolocumab** | PCSK9 inhibitor | FOURIER | Reduces LDL + CV events on statin |
| **Colchicine** | Anti-inflammatory | LoDoCo2, COLCOT | Reduces MACE in ACS and stable CAD |
| **Empagliflozin** | SGLT-2i | EMPA-REG + DAPA-HF | Reduces CV death/hospitalisation in HFrEF |
| **Rivaroxaban 2.5mg BD** | Factor Xa | COMPASS | Aspirin + rivaroxaban reduces MACE in stable CAD |

---

## ICD Indications Post-MI

- EF ≤35% despite optimal medical therapy at **≥40 days** post-MI + NYHA class II-III
- Sustained VT/VF >48h post-MI (not due to transient ischaemia)

> **HKMLE TRAP:** Do NOT implant ICD in the first 40 days post-MI - wait for myocardial stunning to resolve and EF to potentially improve.

---

\newpage

# PAGE 13: POST-MI COMPLICATIONS OVERVIEW

## Complications Mnemonic: "PATCH-VALVE"

| Time | Complication |
|---|---|
| 0-24h | **P**rimary VF/VT, **A**rrhythmias, **C**ardiogenic shock |
| 1-3 days | **T**ransient heart block, RV infarction |
| **3-7 days** | **C**atastrophic: Free wall rupture, VSD, papillary rupture |
| Days 1-3 | **H**aemopericardium, acute pericarditis |
| 2-10 weeks | Dressler's syndrome (autoimmune pericarditis) |
| Weeks-months | **V**entricular aneurysm, **A**neurysmal thrombus |
| Ongoing | **L**VF, **E**jection fraction decline |

---

## Mechanical Complications Comparison Table

| Feature | Free Wall Rupture | VSD | Papillary Rupture (MR) |
|---|---|---|---|
| **Timing** | 3-7 days | 3-7 days | 3-7 days |
| **Presentation** | Sudden death, PEA, collapse | New holosystolic murmur + APO | New holosystolic murmur + APO |
| **Murmur** | None (tamponade) | Left lower sternal border | Apex → axilla |
| **Echo** | Pericardial effusion, tamponade | Colour flow: L→R shunt | Flail leaflet, severe MR jet |
| **Swan-Ganz** | RA = RV = PCWP (tamponade) | **O2 step-up RA to RV** | **Large V waves on PCWP** |
| **Definitive Rx** | Emergency surgery | Emergency surgery | Emergency surgery |
| **MI location** | Anterior > inferior | Anterior (apical) or inferior (basal) | Inferior (posterior papillary) > anterior |

> **QUICK SUMMARY:** VSD vs MR - both present with new holosystolic murmur + flash APO post-MI.
> Distinguish by Swan-Ganz: VSD = O2 step-up; MR = large V waves.

---

\newpage

# PAGE 14: VSD POST-MI

## Definition

Rupture of the interventricular septum after MI, creating a VSD with **left-to-right shunting**, causing haemodynamic collapse and acute pulmonary oedema.

## Timing

- Peak: **3-7 days** post-MI
- <1% of STEMIs in reperfusion era

## Pathophysiology

Complete coronary occlusion → large transmural infarction → days 3-7: macrophage infiltration → myocyte digestion → softening → mechanical stress → **septal rupture** → L→R shunt → RV volume overload → RV failure → pulmonary oedema + hypoxia + cardiogenic shock.

## Clinical Features

- Sudden deterioration 3-7 days post-MI
- New loud **holosystolic murmur at left lower sternal border** + parasternal thrill
- Flash pulmonary oedema
- Haemodynamic collapse

## Diagnosis

- **Echo with Colour Flow Doppler**: Direct visualisation + L→R jet
- **Swan-Ganz**: O2 step-up from RA to RV (>8% = significant), elevated PCWP, low CO

## Management - Mnemonic: "VISA"

- **V**asopressors + inotropes
- **I**ntra-aortic Balloon Pump (IABP) - reduces afterload
- **S**urgery - emergency surgical VSD repair (definitive)
- **A**dvanced: Ventricular Assist Devices as bridge

Transcatheter VSD closure in selected patients.

---

\newpage

# PAGE 15: MITRAL REGURGITATION POST-MI

## Definition

Post-MI MR results from **papillary muscle dysfunction or rupture** following MI, leading to acute, severe MR and haemodynamic collapse.

## Anatomy: Papillary Muscles

| Papillary Muscle | Blood Supply | Vulnerable MI |
|---|---|---|
| **Posterior-medial** | Single (RCA only) | **INFERIOR MI** - most common, more likely to rupture |
| **Anterolateral** | Dual (LAD + LCx) | Anterior MI - less common (dual supply protects) |

> **HKMLE TRAP:** Posterior-medial papillary muscle has SINGLE blood supply (RCA) → far more prone to rupture. Post-MI MR is more common in INFERIOR MI!

## Pathophysiology

RCA occlusion → inferior MI → posterior papillary muscle ischaemia/necrosis → rupture (days 3-7) → massive regurgitation into LA (unprepared/not dilated) → acute massive pulmonary oedema → low forward CO → cardiogenic shock.

## Clinical Features

- Sudden deterioration 3-7 days post-MI (inferior usually)
- New **holosystolic murmur at apex radiating to axilla**
- Acute flash pulmonary oedema (may be out of proportion to LV dysfunction)
- Cardiogenic shock

## Diagnosis

- **Echo**: Flail leaflet, posteriorly-directed MR jet, hyperdynamic LV
- **Swan-Ganz**: Prominent **V waves** on PCWP trace, low CO
- **CXR**: Asymmetric pulmonary oedema

## Management

- **Bridge**: IABP, vasodilators (nitroprusside), inotropes
- **Definitive**: Emergency mitral valve surgery (repair preferred)

---

\newpage

# PAGE 16: LV FREE WALL RUPTURE

## Definition

Rupture of the infarcted LV free wall → haemopericardium → cardiac tamponade → usually rapid death.

## Epidemiology

- Complicates **1-3%** of acute MIs
- Risk factors: first MI, anterior MI, large MI, no prior angina, female sex, elderly, late reperfusion
- Peak: **3-7 days** (1/3 in first 24h)

## Pathophysiology

Transmural infarction → days 3-7: macrophage digestion → progressive thinning + softening → mechanical stress → **RUPTURE** → blood enters pericardial space → haemopericardium → cardiac tamponade → PEA → death.

## Three Forms

| Type | Presentation | Outcome |
|---|---|---|
| **Acute (blow-out)** | Sudden death, PEA | Usually fatal |
| **Subacute** | Recurrent chest pain, hypotension, new pericardial effusion | May survive with surgery |
| **Chronic (pseudoaneurysm)** | Contained by pericardium | Risk of delayed rupture |

> **HKMLE TRAP:** **PEA in a patient with recent STEMI = assume free wall rupture until proven otherwise!** Look for: recent STEMI, sudden PEA, echo showing pericardial effusion.

## Beck's Triad (Tamponade)

- Hypotension
- Raised JVP
- Muffled heart sounds

## Management

- **Emergency pericardiocentesis** as temporising measure
- **Emergency surgical repair** (definitive)
- Pseudoaneurysm: Urgent/elective surgical repair (high rupture risk!)

## True Aneurysm vs Pseudoaneurysm

| Feature | True LV Aneurysm | Pseudoaneurysm |
|---|---|---|
| **Wall** | Thinned fibrotic myocardium | **Only pericardium** (no myocardium) |
| **Neck** | Broad | Narrow (pinched) |
| **Rupture risk** | **LOW** | **HIGH** |
| **Treatment** | Medical ± surgical if symptomatic | **Surgery mandatory** |

---

\newpage

# PAGE 17: EARLY POST-MI PERICARDITIS

## Definition

Pericarditis within **1-3 days** of a transmural MI, due to direct epicardial inflammation overlying necrotic myocardium. Also called epistenocardiac pericarditis.

## Mechanism

Transmural MI → myocyte necrosis involving epicardium → inflammatory response → fibrinous pericarditis → pericardial friction rub → pleuritic chest pain → ECG changes localised to infarct territory (often obscured by MI changes).

## Clinical Features

| Feature | Early Post-MI Pericarditis |
|---|---|
| Timing | 1-3 days post-MI |
| Pain | Pleuritic, sharp, positional; worse supine, better sitting forward |
| Physical exam | **Pericardial friction rub** (pathognomonic) |
| ECG | Localised; often masked by MI changes |
| Echo | Small pericardial effusion |

## Treatment

- **Aspirin** (already on aspirin post-MI; preferred over other NSAIDs)
- **Colchicine** added to aspirin to reduce recurrence
- **Avoid ibuprofen and indomethacin** (impair infarct healing)
- **ABSOLUTELY AVOID corticosteroids** (impair myocardial scar formation → rupture risk!)

> **HKMLE TRAP:** STEROIDS ARE CONTRAINDICATED in early post-MI pericarditis. They impair scar formation and may cause myocardial rupture. The HKMLE will offer prednisolone as a tempting option - AVOID!

---

\newpage

# PAGE 18: DRESSLER'S SYNDROME

## Definition

Dressler's syndrome is an **autoimmune pericarditis** (and often pleuritis) occurring **2-10 weeks** after acute MI, due to an immune response (type III hypersensitivity) to cardiac antigens released during necrosis.

## Incidence

- **<1%** of MIs in the modern reperfusion era (previously 3-4%)
- Declining due to smaller infarcts and early reperfusion
- Also occurs post-cardiac surgery = Post-pericardiotomy syndrome

## Pathophysiology

Large MI → cardiac antigen release → 2-10 weeks: autoimmune response → antibodies + T cells attack pericardium and pleura → fibrinous/serofibrinous pericarditis + pleuritis → fever, chest pain, effusion, leukocytosis.

## Clinical Features

| Feature | Description |
|---|---|
| Timing | **2-10 weeks** post-MI (most commonly 2-6 weeks) |
| Fever | Prominent |
| Chest pain | Pleuritic |
| Friction rub | Often present |
| Leukocytosis | Present |
| ESR/CRP | Elevated |
| Pleural effusion | Common (may be dominant) |
| Pericardial effusion | Common |
| Troponin | NORMAL or mildly elevated |

## Management

| Treatment | Detail |
|---|---|
| **NSAIDs** (aspirin or ibuprofen) | First-line |
| **Colchicine** | Added to reduce recurrence |
| **Corticosteroids** | Reserve for refractory cases (SAFE here - infarct is healed!) |

---

## Dressler's vs Early Pericarditis Comparison

| Feature | Early Pericarditis | Dressler's Syndrome |
|---|---|---|
| Timing | 1-3 days | **2-10 weeks** |
| Mechanism | Direct epicardial necrosis | **Autoimmune** |
| Fever | Mild | **Prominent** |
| ESR | Mildly elevated | **Markedly elevated** |
| Pleural effusion | Uncommon | **Common** |
| Steroids | **CONTRAINDICATED** | Can use for refractory cases |

---

**COMMON EXAM QUESTION:**

Q: A 60-year-old man presents 4 weeks after a large anterior STEMI with fever, pleuritic chest pain, and elevated ESR. Troponin is normal. Diagnosis and treatment?

A: **Dressler's syndrome.** Treatment: **aspirin/NSAIDs + colchicine.** If refractory: corticosteroids (safe as infarct is healed).

---

\newpage

# PAGE 19: LV ANEURYSM

## Definition

LV aneurysm is a **localised dyskinetic bulge** of the LV wall consisting of fibrotic scar tissue that paradoxically expands during systole. This is a **true aneurysm** (all myocardial layers present, though fibrotic).

## Incidence and Timing

- Complicates **3-15%** of large transmural MIs (particularly anterior-apical, LAD territory)
- Develops **weeks to months** after MI
- More common with late/failed reperfusion (larger infarcts)

## Pathophysiology

Large transmural anterior MI (LAD) → extensive myocyte necrosis → fibrotic scar → scar cannot contract (dyskinetic) → during systole: healthy LV squeezes → scar bulges out → reduces effective stroke volume → blood stasis → **mural thrombus** + persistent ST elevation + arrhythmias.

## Clinical Features

| Feature | LV Aneurysm |
|---|---|
| **Timing** | Weeks to months post-MI |
| **ECG** | **Persistent ST elevation >2 weeks in territory of old MI** |
| Symptoms | Heart failure, dyspnoea, palpitations |
| Complications | Mural thrombus + embolism, VT/VF, heart failure |
| **Echo** | Dyskinetic wall, thinned fibrotic wall, ± thrombus |

> **HKMLE TRAP:** **Persistent ST elevation >2 weeks after MI = LV aneurysm until proven otherwise!** Distinguish from reinfarction (troponin rise) and pericarditis (clinical features).

## Management

| Indication | Treatment |
|---|---|
| Asymptomatic, small | Medical (ACEi, beta-blocker, anticoagulation if thrombus) |
| Large aneurysm + HF | LV reconstruction surgery (Dor procedure) |
| Refractory VT | Surgical resection + ablation |
| Mural thrombus | Anticoagulation 3-6 months |

---

\newpage

# PAGE 20: MURAL THROMBUS

## Definition

A mural thrombus is a **blood clot adherent to the LV endocardial surface**, most commonly at the **apex**, following MI. Forms in areas of akinesis/dyskinesis where blood stagnates.

## Pathophysiology - Virchow's Triad

1. **Endothelial damage:** necrotic endocardium overlying MI
2. **Stasis:** akinetic/dyskinetic wall → blood stagnates
3. **Hypercoagulability:** acute phase proteins elevated after MI

→ Platelet adhesion → fibrin deposition → MURAL THROMBUS → risk of embolisation → **stroke, visceral infarction, limb ischaemia**

## Incidence

- Large anterior MI: up to **20%** develop mural thrombus
- Most common in first **2 weeks**; LV aneurysm = long-term risk

## Investigations

- **Echocardiography (with contrast):** Gold standard; apical 4-chamber view
- **Cardiac MRI:** Highest sensitivity (detects small thrombi missed by echo)

## Management - Mnemonic: "WANE"

- **W**arfarin (INR 2-3): Traditional therapy, 3-6 months (or until echo shows thrombus resolution)
- **A**nticoagulation with NOAC: Rivaroxaban, apixaban increasingly used
- **N**ote: DAPT alone is insufficient - full anticoagulation needed
- **E**cho at 3-6 months: reassess for thrombus resolution

> **HKMLE TRAP - Triple Therapy:** Aspirin + P2Y12 + anticoagulant = very high bleeding risk. Minimise duration; use HAS-BLED score to guide.

---

**COMMON EXAM QUESTION:**

Q: 5 days after a large anterior STEMI treated with thrombolysis, a 55-year-old develops sudden left hemiplegia. Likely diagnosis?

A: **Mural thrombus → cardioembolic stroke** from thrombus in the akinetic LV apex. Management: anticoagulation.

---

\newpage

# PAGE 21: DRUG TRAPS TABLE

| Drug / Class | The TRAP | Correct Action |
|---|---|---|
| **Morphine in ACS** | Reduces P2Y12 inhibitor absorption → worse outcomes | Reserve for truly refractory pain only |
| **Oxygen in ACS** | Hyperoxia worsens outcomes if SpO2 ≥94% | O2 only if SpO2 <94% |
| **GTN in RV infarction** | Causes catastrophic hypotension (RV is preload-dependent) | IV fluids, NOT nitrates |
| **GTN + PDE-5 inhibitors** | Sildenafil/tadalafil + GTN = severe hypotension | Ask about ED meds in ALL chest pain patients! |
| **Clopidogrel + Omeprazole** | Omeprazole inhibits CYP2C19 → less clopidogrel activation | Use **pantoprazole** instead |
| **Aspirin + Ibuprofen** | Ibuprofen competitively inhibits aspirin's COX-1 binding | Take aspirin 2h before ibuprofen or avoid |
| **Nitrate tolerance** | Continuous nitrate use → tolerance within 24h | Always have 8-12h nitrate-free window |
| **Beta-blockers in acute LVF/shock** | Contraindicated in acute pulmonary oedema/cardiogenic shock | Start only when haemodynamically stable |
| **Thrombolytics in aortic dissection** | Catastrophic haemorrhage and death | Always rule out dissection before lysis |
| **Streptokinase repeat** | Antibodies form → anaphylaxis + treatment failure if used within 5 years | Use alteplase or tenecteplase |
| **Prasugrel in TIA/stroke, >75y, <60kg** | Risk of net harm (excess bleeding) | Use ticagrelor or clopidogrel instead |
| **Fondaparinux alone for PCI** | Risk of catheter thrombosis | Add UFH bolus at time of PCI |
| **Steroids in early post-MI pericarditis** | Impairs myocardial scar formation → rupture risk | Aspirin + colchicine; NO steroids in acute phase |
| **Digoxin in WPW + AF** | Accelerates accessory pathway conduction → VF | ABSOLUTELY CONTRAINDICATED in WPW + AF |
| **NSAIDs (non-aspirin) post-MI** | Increase CV events; impair infarct healing | Avoid all NSAIDs post-MI except aspirin |

---

\newpage

# PAGE 22: NOTABLE TRIALS TABLE

| Trial | Drug/Intervention | Finding | HKMLE Relevance |
|---|---|---|---|
| **PLATO** | Ticagrelor vs clopidogrel | Ticagrelor reduces CV death, MI, stroke + all-cause mortality in ACS | Ticagrelor preferred in ACS |
| **TRITON-TIMI 38** | Prasugrel vs clopidogrel | Prasugrel superior in STEMI PCI but more major bleeding | Know contraindications (TIA/stroke, >75y, <60kg) |
| **CURE** | Clopidogrel vs placebo | Clopidogrel + aspirin reduces MACE in NSTEMI | DAPT concept established |
| **GUSTO** | tPA vs streptokinase | tPA superior: fewer deaths, slight excess ICH | tPA better but more ICH risk |
| **DANAMI-2** | Primary PCI vs thrombolysis | Primary PCI superior in mortality + reinfarction + stroke | pPCI is gold standard |
| **COURAGE** | PCI + OMT vs OMT alone | No difference in mortality/MI (stable angina) | Stable angina: medical therapy first; PCI for symptoms |
| **ISCHEMIA** | Early invasive vs conservative | No reduction in CV death/MI with early invasive in stable ischaemia | Do NOT rush to cath in stable patients |
| **FREEDOM** | PCI vs CABG in multivessel DM | CABG superior to PCI in diabetics (lower MI, mortality) | DM + multivessel = prefer CABG |
| **SYNTAX** | PCI vs CABG in multivessel/LMS | Low SYNTAX: PCI = CABG; High SYNTAX: CABG superior | Use SYNTAX score to decide |
| **SHOCK Trial** | Early revascularisation vs stabilisation | Early PCI reduces 6-month + long-term mortality in cardiogenic shock | Cardiogenic shock = urgent revascularisation |
| **COLCOT** | Colchicine post-MI | Colchicine 0.5mg OD post-MI reduces MACE | New secondary prevention option |
| **LoDoCo2** | Colchicine in stable CAD | Reduces MACE in stable CAD | Secondary prevention beyond acute phase |
| **FOURIER** | Evolocumab (PCSK9i) + statin | Reduces LDL by 59% + CV events | Add PCSK9i if LDL not at target |
| **EMPA-REG** | Empagliflozin in T2DM + CVD | Reduces CV death, HF hospitalisation | SGLT2i post-MI if DM or HFrEF |
| **DAPA-HF** | Dapagliflozin in HFrEF | Reduces CV death/HF regardless of DM | SGLT2i for HFrEF post-MI |
| **COMPASS** | Rivaroxaban 2.5mg BD + aspirin | Reduces MACE in stable CAD (more bleeding) | Very low-dose rivaroxaban option |
| **2023 ESC ACS Guidelines** (PMID 37622654) | Guideline update | hs-Troponin 0/1h; GRACE preferred; colchicine added; morphine de-emphasised | Current standard of care |
| **2025 ACC/AHA ACS Guidelines** (PMID 40014670) | Guideline update | Comprehensive ACS management update | Most current guideline |

---

\newpage

# PAGE 23: MASTER MNEMONICS TABLE

| Topic | Mnemonic | Stands For |
|---|---|---|
| **Risk Factors for ACS** | SAD FISHES | Smoking, Age, Diabetes, Family hx, Ischaemia, Sedentary, HTN, Elevated lipids, Sex |
| **Causes of Angina** | CASH BAD | CAD, AS, Spasm, HCM, Bridging, Anaemia, Dysfunctional endothelium |
| **Acute ACS Management** | BATMAN | Beta-blocker, Aspirin, Thienopyridine, Morphine (cautious), Anticoagulant, Nitrate |
| **Secondary Prevention Post-MI** | ABCDE | Aspirin+ACEi, Beta-blocker, Cholesterol (statin), DAPT+Diabetes, Exercise+Eplerenone |
| **Post-MI Complications** | PATCH-VALVE | Pulseless VF, Arrhythmias, Cardiogenic shock, Tamponade, Haemopericardium, VSD, Aneurysm, LVF, Valve (MR), Embolism |
| **Reperfusion Success** | STAR | ST resolution, Troponin early peak, AIVR, Relief of pain |
| **ACS Investigations** | BE CAREFUL | Bloods/troponin, ECG, CBC, ABG, Renal function, Echo, Fasting lipids, Urine, LFTs |
| **Biomarker Rise Times** | TroM CLCK | Troponin (3-6h), Myoglobin (1-3h), CK-MB (3-6h), LDH (12-24h) |
| **High-Risk NSTEMI** | SHOCK STAR | Shock, HF, Ongoing ischaemia, CHB, K(mechanical), ST aVR, Troponin, Arrhythmia, Recurrent ECG |
| **Thrombolysis Contraindications** | HBAS-NO | Haemorrhagic stroke, Bleeding, Aortic dissection, Severe HTN, Neurosurgery, Ongoing bleed |
| **CCS Angina** | 1-2-3-REST | I=strenuous only, II=brisk walking, III=1-2 blocks, IV=rest |
| **Killip Classes** | 1234 MORE DEATH | I=No failure (6%), II=S3+crackles (17%), III=Pulm oedema (38%), IV=Shock (67%) |
| **Non-ACS Troponin Rise** | HEART FAILURE MAPS | HF, Endocarditis, Arrhythmia, RV strain, Takotsubo, Failure(renal), AF ablation, ICH, Lightning, Undergoing surgery, Rhabdo, Endurance, Myocarditis, Aortic dissection, Pneumonitis/Sepsis |
| **Virchow's Triad (mural thrombus)** | E-S-H | Endothelial damage, Stasis, Hypercoagulability |
| **Mural Thrombus Treatment** | WANE | Warfarin, Anticoagulation (NOAC option), Note DAPT insufficient, Echo follow-up |
| **Posterior MI recognition** | BRAT | Big R in V1-V2, Reciprocal ST depression, Associated inferior MI, Tall T waves V1 |
| **Beck's Triad (tamponade)** | HMJ | Hypotension, Muffled heart sounds, JVP raised |

---

\newpage

# PAGE 24: CROSS-MODULE LINKS

| This Topic | Links To | Why It Matters |
|---|---|---|
| **ACS / MI** | Heart Failure (Module 1B) | LV dysfunction post-MI → HF; EF monitoring, ACEi/BB titration |
| **ACS / MI** | Arrhythmias (Module 1C) | VF (first hour), VT (scar re-entry), complete HB (inferior MI), AIVR (reperfusion) |
| **ACS / MI** | Cardiogenic Shock (Module 1D) | Killip IV; IABP, revascularisation, ECMO/VAD |
| **Stable Angina** | Aortic Stenosis (Module 1E) | AS causes angina without CAD; same ECG, same symptoms - different cause |
| **Stable Angina** | Chronic Stable Coronary Disease | Stress testing, revascularisation decisions (COURAGE/ISCHEMIA trial) |
| **STEMI reperfusion** | Stroke/Thrombolysis (Neurology) | Stroke thrombolysis indications mirror MI; haemorrhagic transformation |
| **Mural Thrombus** | Stroke (Neurology) | Cardioembolic stroke - most commonly from LV thrombus or AF |
| **Dressler's Syndrome** | Pericarditis / Pericardial Disease | Same management; also post-cardiac surgery |
| **DAPT** | GI Bleeding (GI Module) | PPI co-prescription with DAPT; GI bleed on anticoagulation |
| **DAPT + Anticoagulation** | Atrial Fibrillation (Module 1C) | Triple therapy - AF + STEMI requiring PCI; duration, HAS-BLED |
| **PCSK9 inhibitors** | Familial Hypercholesterolaemia | PCSK9i in FH when statins insufficient |
| **Cocaine-induced MI** | Toxicology Module | Cocaine = vasospasm + thrombus; benzos + GTN; AVOID beta-blockers (unopposed alpha → worse spasm) |
| **Type 2 MI** | Anaemia, Sepsis, Resp Failure | Treat underlying cause; NOT thrombolytics |
| **Prinzmetal Angina** | Raynaud's, Vasospasm | CCBs (NOT beta-blockers); nitroglycerin; occurs at rest/early morning |
| **Spontaneous Coronary Dissection** | Obstetrics Module | Peripartum women; young women; no atherosclerosis; conservative Rx preferred |
| **SGLT-2 inhibitors** | Diabetes + Cardiovascular | Empagliflozin/dapagliflozin reduce CV death in HFrEF and diabetics post-MI |

---

## FINAL RED FLAGS SUMMARY

1. Central crushing chest pain >20 min, not relieved by GTN → STEMI protocol
2. Diaphoresis + nausea + vomiting with chest pain → autonomic activation = ischaemia!
3. New ST elevation in 2 contiguous leads → STEMI NOW
4. New LBBB + chest pain → STEMI equivalent → treat as STEMI
5. Diffuse ST depression + ST elevation in aVR → left main stem occlusion
6. Post-MI patient with sudden PEA → free wall rupture until proven otherwise
7. Post-MI day 3-7 + new holosystolic murmur + haemodynamic collapse → VSD or MR
8. Persistent ST elevation >2 weeks post-MI → LV aneurysm
9. Post-MI fever + pleuritic chest pain at 2-10 weeks → Dressler's syndrome
10. Young woman + acute MI + NO risk factors → spontaneous coronary dissection or Prinzmetal

---

## TOP EXAM Q&A RAPID REFERENCE

| Scenario | Answer |
|---|---|
| Which biomarker rises first? | Myoglobin (1-3h) |
| Gold standard biomarker? | High-sensitivity Troponin |
| Biomarker for reinfarction? | CK-MB (returns to normal sooner) |
| New LBBB + chest pain = ? | STEMI equivalent - activate cath lab |
| Door-to-balloon time target? | <90 min (in-hospital), <120 min total FMC |
| GTN contraindicated in? | RV infarction, hypotension, PDE-5 inhibitor use |
| Morphine in ACS? | AVOID routinely |
| O2 in ACS? | Only if SpO2 <94% |
| Post-MI PEA? | Free wall rupture - emergency echo + surgery |
| Posterior MI ECG? | ST depression V1-V2 + tall R - check V7-V9 |
| Best P2Y12 in ACS? | Ticagrelor (PLATO trial) |
| Clopidogrel + best PPI? | Pantoprazole (least CYP2C19 inhibition) |
| ICD post-MI: when? | ≥40 days post-MI if EF ≤35% |
| Stable angina: PCI vs OMT? | OMT equivalent for prognosis (COURAGE); PCI for symptoms |
| CABG preferred when? | DM + multivessel disease (FREEDOM trial) |
| Dressler's timing? | 2-10 weeks post-MI |
| Early pericarditis steroids? | CONTRAINDICATED |
| LV pseudoaneurysm? | Narrow neck, no myocardium in wall, HIGH rupture risk → surgery |
| AIVR post-thrombolysis? | Benign reperfusion arrhythmia - no treatment needed |
| VSD vs MR (Swan-Ganz)? | VSD = O2 step-up RA→RV; MR = large V waves on PCWP |

---

*Sources: Goldman-Cecil Medicine (International Edition); Harrison's Principles of Internal Medicine 22E (2025); Robbins & Kumar Pathologic Basis of Disease; Rosen's Emergency Medicine; 2023 ESC ACS Guidelines (PMID 37622654); 2025 ACC/AHA ACS Guidelines (PMID 40014670)*

pandoc /home/daytona/workspace/hkmle-acs/ACS_HKMLE_Notes.md \ -o /home/daytona…

pandoc --list-input-formats 2>/dev/null | head -5; pandoc --version | head -3; w…

python3 -c " from pypdf import PdfReader reader = PdfReader('/home/daytona/works…

python3 -c " from pypdf import PdfReader reader = PdfReader('/home/daytona/works…

~/hkmle-acs/HKMLE_ACS_Anki_Flashcards.txt

HKMLE MODULE 1A - ACUTE CORONARY SYNDROME
Anki Cloze Flashcards
Generated: July 2026
Format: Cloze deletion | Tags at end of each card
============================================================

--- ACS SPECTRUM & DEFINITIONS ---

1. In the ACS spectrum, troponin is {{c1::normal}} in unstable angina and {{c2::elevated}} in NSTEMI. #CutOff #ACS

2. The ONLY difference between unstable angina and NSTEMI is {{c1::troponin elevation (elevated in NSTEMI, normal in UA)}}. #HKMLEtrap #ACS

3. STEMI is characterised by persistent ST elevation for more than {{c1::20 minutes}} with myocyte necrosis. #CutOff #ACS #ECG

4. In STEMI, the underlying mechanism is {{c1::complete (total) coronary occlusion}}. #ACS

5. In NSTEMI, the underlying mechanism is {{c1::subtotal (partial) coronary occlusion}} causing subendocardial infarction. #ACS

6. Type 2 MI is caused by {{c1::supply-demand mismatch}} (e.g., anaemia, tachycardia, hypotension). #ACS

7. Management of Type 2 MI is directed at {{c1::treating the underlying cause}}, NOT thrombolytics. #HKMLEtrap #Management #ACS

--- CORONARY ARTERY TERRITORIES ---

8. LAD occlusion causes {{c1::anterior}} MI and corresponds to ECG leads {{c2::V1-V4}}. #ECG #ACS

9. RCA occlusion causes {{c1::inferior}} MI and corresponds to ECG leads {{c2::II, III, aVF}}. #ECG #ACS

10. LCx occlusion causes {{c1::lateral}} MI and corresponds to ECG leads {{c2::I, aVL, V5-V6}}. #ECG #ACS

11. RCA occlusion is associated with {{c1::bradycardia and heart block}} due to SA/AV node involvement. #ECG #Complication #ACS

12. LAD occlusion carries the {{c1::worst prognosis}} and the highest risk of {{c2::cardiogenic shock}}. #ACS #Complication

--- INFARCT EVOLUTION & TIMING ---

13. Peak rupture risk (free wall rupture, VSD, papillary rupture) occurs {{c1::3-7 days}} post-MI. #Timing #HKMLEtrap #Complication

14. At 3-7 days post-MI, histology shows {{c1::macrophage infiltration}} causing softening — this is why rupture peaks at this time. #Timing #Complication

15. Irreversible myocyte necrosis begins after approximately {{c1::20-40 minutes}} of ischaemia. #CutOff #ACS

16. Q waves develop in STEMI {{c1::hours to days}} after onset and persist {{c2::permanently}} as a scar marker. #ECG #Timing

17. Hyperacute T waves appear {{c1::within minutes}} of STEMI onset. #ECG #Timing

--- STABLE ANGINA ---

18. Stable angina is caused by a fixed coronary stenosis of more than {{c1::70%}}. #CutOff #ACS

19. Exertional angina is typically relieved by rest or GTN within {{c1::1-5 minutes}}. #CutOff #ACS

20. Angina does NOT radiate to the {{c1::trapezius}} — trapezius radiation indicates {{c2::pericarditis}}. #HKMLEtrap #ACS

21. CCS Class I angina occurs {{c1::only with strenuous exertion}} with no limitation of ordinary activity. #CutOff #ACS

22. CCS Class II angina causes slight limitation — symptoms with {{c1::brisk walking, climbing stairs, or after meals}}. #CutOff #ACS

23. CCS Class III angina causes marked limitation — symptoms walking {{c1::1-2 blocks on level ground or 1 flight of stairs}}. #CutOff #ACS

24. CCS Class IV angina occurs at {{c1::rest or with any physical activity}}. #CutOff #ACS

25. ETT (exercise stress test) is contraindicated if the resting ECG shows {{c1::LBBB, WPW, or significant ST depression}}. #HKMLEtrap #Contraindication #Investigation

26. The gold standard investigation for coronary anatomy in stable angina is {{c1::invasive coronary angiography}}. #Investigation #ACS

27. First-line anti-anginal agent for stable angina is {{c1::beta-blocker}}. #Management #ACS

28. Target LDL in a patient with stable angina/established CAD is {{c1::<1.8 mmol/L}} (ESC) or {{c2::<1.4 mmol/L}} (ESC high-risk). #CutOff #Management #ACS

29. Nitrate tolerance is prevented by having a nitrate-free window of {{c1::8-12 hours}} daily. #HKMLEtrap #Management #ACS

30. CABG is preferred over PCI when the patient has {{c1::triple vessel disease + diabetes mellitus}} (FREEDOM trial). #Management #ACS

31. In stable angina, PCI vs OMT alone shows {{c1::no difference in mortality}} — PCI is for symptom control only (COURAGE trial). #HKMLEtrap #Management #ACS

--- NSTEMI / UNSTABLE ANGINA ---

32. Unstable angina has three presentations: rest angina, {{c1::new-onset CCS ≥III angina}}, and {{c2::crescendo angina}}. #ACS

33. ST elevation in aVR with diffuse ST depression indicates {{c1::left main stem (LMS) or proximal LAD occlusion}} — treat as STEMI equivalent. #HKMLEtrap #ECG #ACS

34. ST depression in V1-V2 with tall R waves suggests {{c1::posterior MI}} — confirm with {{c2::posterior leads V7-V9}}. #HKMLEtrap #ECG #ACS

35. TIMI score of 0-1 carries a 14-day MACE rate of {{c1::~5%}} and warrants {{c2::medical (conservative) management}}. #CutOff #ACS

36. TIMI score of 6-7 carries a 14-day MACE rate of {{c1::~41%}} and warrants {{c2::urgent invasive strategy <2 hours}}. #CutOff #ACS

37. A GRACE score >{{c1::140}} indicates high risk with in-hospital mortality >3% and requires early invasive strategy within {{c2::24 hours}}. #CutOff #ACS

38. A GRACE score <{{c1::109}} indicates low risk with in-hospital mortality <1%. #CutOff #ACS

39. ESC 2023 recommends {{c1::GRACE score}} (not TIMI) as the preferred risk stratification tool for NSTEMI. #HKMLEtrap #ACS

--- STEMI ---

40. STEMI in lead V4R indicates {{c1::right ventricular infarction}} from {{c2::proximal RCA}} occlusion. #ECG #ACS

41. ST elevation criteria in limb leads for STEMI is ≥{{c1::1mm}}. #CutOff #ECG #ACS

42. ST elevation criteria in V2-V3 for STEMI in men is ≥{{c1::2mm}} (≥2.5mm if age <40 years). #CutOff #ECG #ACS

43. ST elevation criteria in V2-V3 for STEMI in women is ≥{{c1::1.5mm}}. #CutOff #ECG #ACS

44. New LBBB with acute chest pain is treated as {{c1::STEMI equivalent}}. #HKMLEtrap #ECG #ACS

45. Sgarbossa criterion: concordant ST elevation ≥1mm in leads with positive QRS scores {{c1::3 points}}. #ECG #CutOff #ACS

46. Sgarbossa criterion: concordant ST depression ≥1mm in V1-V3 scores {{c1::3 points}}. #ECG #CutOff #ACS

47. Sgarbossa criterion: discordant ST elevation ≥5mm scores {{c1::2 points}}. #ECG #CutOff #ACS

48. A Sgarbossa score of ≥{{c1::3}} indicates high probability of MI in the setting of LBBB. #CutOff #ECG #ACS

49. Killip Class I 30-day mortality is {{c1::~6%}}. #CutOff #ACS

50. Killip Class II 30-day mortality is {{c1::~17%}}. #CutOff #ACS

51. Killip Class III 30-day mortality is {{c1::~38%}}. #CutOff #ACS

52. Killip Class IV (cardiogenic shock) 30-day mortality is {{c1::~67%}}. #CutOff #ACS

--- ECG INTERPRETATION ---

53. In pericarditis, ST elevation is {{c1::concave (saddle-shaped)}} and {{c2::diffuse}} (all leads except aVR, V1). #ECG #ACS

54. In STEMI, ST elevation is {{c1::convex (tombstone-shaped)}} and {{c2::territorial}} (specific coronary territory). #ECG #ACS

55. Reciprocal ST changes are {{c1::present}} in STEMI and {{c2::absent}} in pericarditis. #ECG #HKMLEtrap #ACS

56. PR segment depression is a feature of {{c1::pericarditis}}, not STEMI. #ECG #HKMLEtrap #ACS

57. Q waves are {{c1::absent}} in pericarditis but {{c2::develop over hours}} in STEMI. #ECG #ACS

58. Mobitz II heart block post-MI indicates {{c1::anterior MI (LAD territory)}}, carries a {{c2::poor prognosis}}, and requires {{c3::pacing}}. #ECG #HKMLEtrap #Management #ACS

59. Complete heart block from anterior MI has an escape rate of {{c1::<40 bpm}} and {{c2::very poor prognosis}}. #ECG #CutOff #ACS

60. Complete heart block from inferior MI has an escape rate of {{c1::>40 bpm}} and {{c2::may resolve spontaneously}}. #ECG #ACS

--- CARDIAC BIOMARKERS ---

61. The first cardiac biomarker to rise after MI is {{c1::myoglobin}}, rising within {{c2::1-3 hours}}. #Investigation #Timing #ACS

62. The gold standard biomarker for diagnosing MI is {{c1::high-sensitivity troponin I or T}}. #Investigation #ACS

63. Troponin begins to rise at {{c1::3-6 hours}}, peaks at {{c2::12-24 hours}}, and returns to normal at {{c3::5-14 days}}. #Timing #Investigation #ACS

64. CK-MB is used (not troponin) to detect {{c1::reinfarction}}, because it returns to normal within {{c2::48-72 hours}}. #HKMLEtrap #Investigation #ACS

65. The hs-Troponin 0h/1h rule-OUT requires hs-TnT <{{c1::5 ng/L}} at 0h AND change <{{c2::4 ng/L}} at 1h. #CutOff #Investigation #ACS

66. The hs-Troponin 0h/1h rule-IN requires hs-TnT >{{c1::52 ng/L}} at 0h OR change ≥{{c2::6 ng/L}} at 1h. #CutOff #Investigation #ACS

67. A troponin that is elevated but stable or falling suggests {{c1::chronic myocardial injury}}, not acute MI. #HKMLEtrap #Investigation #ACS

68. Troponin can be elevated in PE due to {{c1::right heart strain}}. #HKMLEtrap #Investigation #ACS

69. Troponin can be elevated in renal failure due to {{c1::impaired clearance}} (not necessarily ACS). #HKMLEtrap #Investigation #ACS

70. Takotsubo (stress) cardiomyopathy causes {{c1::troponin elevation}} without obstructive coronary disease. #HKMLEtrap #Investigation #ACS

--- ACS MANAGEMENT ---

71. The acute ACS management mnemonic is {{c1::BATMAN}} (Beta-blocker, Aspirin, Thienopyridine, Morphine, Anticoagulant, Nitrate). #Management #ACS

72. Aspirin loading dose in ACS is {{c1::300mg}}, followed by a maintenance dose of {{c2::75mg daily}}. #Management #CutOff #ACS

73. Morphine should be {{c1::avoided routinely}} in ACS because it reduces {{c2::oral P2Y12 inhibitor absorption}} → worse outcomes. #HKMLEtrap #Management #ACS

74. Supplemental oxygen should only be given in ACS if SpO2 is {{c1::<94%}}. #HKMLEtrap #Management #CutOff #ACS

75. GTN is absolutely contraindicated in ACS if SBP is {{c1::<90 mmHg}}. #Contraindication #Management #ACS

76. GTN is absolutely contraindicated in {{c1::right ventricular (RV) infarction}}. #HKMLEtrap #Contraindication #Management #ACS

77. GTN is absolutely contraindicated if the patient has used a PDE-5 inhibitor (sildenafil) within {{c1::24 hours}}, or tadalafil within {{c2::48 hours}}. #Contraindication #Management #ACS

78. The preferred P2Y12 inhibitor in ACS is {{c1::ticagrelor}} (PLATO trial). #Management #ACS

79. Ticagrelor loading dose is {{c1::180mg}}, maintenance {{c2::90mg twice daily}}. #Management #CutOff #ACS

80. A known side effect of ticagrelor (occurring in ~10% of patients) is {{c1::dyspnoea}}. #Management #ACS

81. Prasugrel is contraindicated in patients with {{c1::prior stroke/TIA}}, age {{c2::>75 years}}, or weight {{c3::<60kg}}. #Contraindication #Management #ACS

82. Clopidogrel is a prodrug requiring activation by {{c1::CYP2C19}}. #Management #HKMLEtrap #ACS

83. If a PPI is required alongside clopidogrel, use {{c1::pantoprazole}} (least CYP2C19 inhibition). #HKMLEtrap #Management #ACS

84. Omeprazole reduces clopidogrel efficacy by {{c1::inhibiting CYP2C19}}, thereby reducing its activation. #HKMLEtrap #Management #ACS

85. Minimum duration of DAPT after PCI for ACS is {{c1::12 months}}. #CutOff #Management #ACS

86. Preferred anticoagulant in NSTEMI/UA (non-PCI) is {{c1::enoxaparin (LMWH)}} or {{c2::fondaparinux}}. #Management #ACS

87. Fondaparinux cannot be used as the sole anticoagulant for PCI because of the risk of {{c1::catheter thrombosis}}. #HKMLEtrap #Contraindication #Management #ACS

88. When fondaparinux is used and PCI is needed, add {{c1::UFH bolus}} at the time of the procedure. #Management #ACS

89. Bivalirudin is the preferred anticoagulant during PCI when the patient has a history of {{c1::heparin-induced thrombocytopenia (HIT)}}. #Management #ACS

--- REPERFUSION ---

90. Door-to-balloon (FMC-to-balloon) target for primary PCI is {{c1::<90 minutes}} for in-hospital presentations. #CutOff #Management #ACS

91. Total FMC-to-balloon time target (including transfer) is {{c1::<120 minutes}}. #CutOff #Management #ACS

92. If pPCI is not available within 120 minutes of FMC, give {{c1::thrombolysis}} within {{c2::10 minutes of diagnosis}}. #Management #NextBestStep #ACS

93. AIVR (accelerated idioventricular rhythm, rate 60-120 bpm) post-thrombolysis is a {{c1::benign reperfusion arrhythmia}} requiring {{c2::no treatment}}. #HKMLEtrap #Management #ACS

94. Successful reperfusion is indicated by ST resolution of ≥{{c1::50%}} within {{c2::90 minutes}}. #CutOff #ACS

95. If thrombolysis fails (no ST resolution >50% at 60-90 min), next best step is {{c1::urgent rescue PCI}} (do NOT repeat thrombolysis). #NextBestStep #Management #ACS

96. Streptokinase should be avoided if it was previously used within {{c1::5 years}} due to {{c2::antibody formation and anaphylaxis risk}}. #HKMLEtrap #Contraindication #Management #ACS

97. Absolute contraindication to thrombolysis: haemorrhagic stroke {{c1::at any time in the past}}. #Contraindication #ACS

98. Absolute contraindication to thrombolysis: ischaemic stroke within {{c1::3 months}}. #Contraindication #CutOff #ACS

99. Absolute contraindication to thrombolysis: neurosurgery or significant head trauma within {{c1::3 months}}. #Contraindication #CutOff #ACS

100. Absolute contraindication to thrombolysis: severe uncontrolled hypertension (SBP >{{c1::180 mmHg}}). #Contraindication #CutOff #ACS

101. Suspected aortic dissection is an absolute contraindication to {{c1::thrombolysis}}. #HKMLEtrap #Contraindication #ACS

--- SECONDARY PREVENTION ---

102. Post-MI secondary prevention mnemonic is {{c1::ABCDE}} (Aspirin+ACEi, Beta-blocker, Cholesterol, DAPT+Diabetes, Exercise+Eplerenone). #Management #ACS

103. High-intensity statin (atorvastatin 40-80mg) is indicated in all post-MI patients with a target LDL of {{c1::<1.4 mmol/L}} (ESC). #Management #CutOff #ACS

104. An ICD is indicated post-MI when EF is ≤{{c1::35%}} at ≥{{c2::40 days}} post-MI with NYHA Class II-III. #Management #CutOff #ACS

105. An ICD should NOT be implanted in the first {{c1::40 days}} post-MI even if EF is severely reduced. #HKMLEtrap #Contraindication #Timing #ACS

106. Eplerenone (aldosterone antagonist) is indicated post-MI if EF <{{c1::35%}} with HF or diabetes. #Management #CutOff #ACS

107. PCSK9 inhibitors (e.g., evolocumab) are added when {{c1::LDL is not at target on maximal statin therapy}}. #Management #ACS

108. Colchicine 0.5mg OD post-MI reduces MACE — evidence from the {{c1::COLCOT}} trial. #Management #ACS

109. The PLATO trial showed {{c1::ticagrelor}} was superior to clopidogrel in ACS, including reducing {{c2::all-cause mortality}}. #ACS

110. The FREEDOM trial showed {{c1::CABG}} is superior to PCI in patients with {{c2::multivessel disease + diabetes}} (lower MI and mortality). #Management #ACS

111. The COURAGE trial showed that in stable angina, {{c1::PCI + OMT is equivalent to OMT alone}} for preventing mortality and MI. #HKMLEtrap #Management #ACS

112. The SHOCK trial showed that {{c1::early revascularisation (PCI)}} reduces mortality in {{c2::cardiogenic shock}} post-STEMI. #Management #ACS

--- POST-MI COMPLICATIONS ---

113. Post-MI mechanical complications (VSD, free wall rupture, papillary rupture) peak at {{c1::3-7 days}} — the time of maximum myocardial softening. #Timing #HKMLEtrap #Complication

114. VSD post-MI is distinguished from acute MR on Swan-Ganz by {{c1::oxygen step-up from RA to RV}} (>8% is significant). #Investigation #HKMLEtrap #Complication

115. Acute MR post-MI is distinguished from VSD on Swan-Ganz by {{c1::large V waves on PCWP tracing}}. #Investigation #HKMLEtrap #Complication

116. The murmur of post-MI VSD is a {{c1::holosystolic murmur loudest at the left lower sternal border}}. #ACS #Complication

117. The murmur of post-MI acute MR (papillary rupture) is a {{c1::holosystolic murmur at the apex radiating to the axilla}}. #ACS #Complication

118. Definitive treatment for post-MI VSD, acute MR, and free wall rupture is {{c1::emergency cardiac surgery}}. #Management #Complication #ACS

119. Bridge therapy for post-MI VSD and acute MR includes {{c1::IABP (intra-aortic balloon pump)}} + vasopressors + inotropes. #Management #Complication #ACS

--- VSD POST-MI ---

120. Post-MI VSD occurs most commonly in {{c1::anterior}} MI causing an {{c2::apical}} VSD, and {{c3::inferior}} MI causing a {{c4::basal}} VSD. #Complication #ACS

121. Next best step when a new holosystolic murmur at the left sternal border + flash pulmonary oedema develops at day 5 post-STEMI is {{c1::urgent bedside echocardiography}}. #NextBestStep #ACS #Complication

--- MR POST-MI ---

122. Post-MI MR most commonly results from rupture of the {{c1::posterior-medial}} papillary muscle, which has a {{c2::single blood supply (RCA only)}}. #HKMLEtrap #Complication #ACS

123. Post-MI MR is most common after {{c1::inferior MI}} because the posterior-medial papillary muscle is supplied solely by the {{c2::RCA}}. #HKMLEtrap #Complication #ACS

124. The anterolateral papillary muscle has {{c1::dual blood supply (LAD + LCx)}} and is therefore less prone to rupture. #Complication #ACS

--- FREE WALL RUPTURE ---

125. Left ventricular free wall rupture occurs in {{c1::1-3%}} of acute MIs. #CutOff #Complication #ACS

126. Next best step in a post-STEMI patient who develops sudden PEA arrest is {{c1::bedside echocardiography to exclude free wall rupture}}. #NextBestStep #HKMLEtrap #ACS #Complication

127. Beck's triad of cardiac tamponade is: {{c1::hypotension}}, {{c2::raised JVP}}, and {{c3::muffled heart sounds}}. #Complication #ACS

128. Emergency management of free wall rupture is {{c1::pericardiocentesis}} as a bridge followed by {{c2::emergency surgical repair}}. #Management #Complication #ACS

129. A pseudoaneurysm has a {{c1::narrow neck}} and its wall is formed by {{c2::pericardium only (no myocardium)}} — high rupture risk. #HKMLEtrap #Complication #ACS

130. A true LV aneurysm has a {{c1::broad neck}} and contains {{c2::all layers of myocardium (though fibrotic)}} — low rupture risk. #Complication #ACS

131. A pseudoaneurysm requires {{c1::mandatory surgical repair}} due to high rupture risk. #Management #HKMLEtrap #Complication #ACS

--- EARLY POST-MI PERICARDITIS ---

132. Early post-MI pericarditis (epistenocardiac pericarditis) occurs within {{c1::1-3 days}} of a transmural MI. #Timing #Complication #ACS

133. The pathognomonic sign of pericarditis is {{c1::pericardial friction rub}}. #Investigation #ACS

134. Corticosteroids are {{c1::absolutely contraindicated}} in early post-MI pericarditis because they {{c2::impair myocardial scar formation}} increasing rupture risk. #HKMLEtrap #Contraindication #Complication #ACS

135. First-line treatment for early post-MI pericarditis is {{c1::aspirin}} (already prescribed) plus {{c2::colchicine}}. #Management #Complication #ACS

136. Ibuprofen and indomethacin should be avoided in early post-MI pericarditis because they {{c1::impair infarct healing}}. #HKMLEtrap #Contraindication #Complication #ACS

--- DRESSLER'S SYNDROME ---

137. Dressler's syndrome occurs {{c1::2-10 weeks}} after MI (most commonly 2-6 weeks). #Timing #Complication #ACS

138. The incidence of Dressler's syndrome in the modern (reperfusion) era is {{c1::<1%}} of MIs. #CutOff #ACS

139. Dressler's syndrome is caused by {{c1::autoimmune response (type III hypersensitivity)}} to cardiac antigens released during necrosis. #ACS #Complication

140. Key features distinguishing Dressler's from reinfarction: troponin is {{c1::normal}} in Dressler's. #HKMLEtrap #Investigation #ACS

141. Prominent {{c1::fever}} and {{c2::pleural effusion}} are characteristic of Dressler's syndrome (less common in early post-MI pericarditis). #Complication #ACS

142. First-line management of Dressler's syndrome is {{c1::NSAIDs (aspirin or ibuprofen) + colchicine}}. #Management #Complication #ACS

143. Corticosteroids in Dressler's syndrome (2-10 weeks post-MI) are {{c1::safe}} (unlike early pericarditis) and used for {{c2::refractory cases}}. #HKMLEtrap #Management #Complication #ACS

144. Dressler's syndrome also occurs after {{c1::cardiac surgery}} (post-pericardiotomy syndrome). #Complication #ACS

--- LV ANEURYSM ---

145. Persistent ST elevation more than {{c1::2 weeks}} after MI suggests {{c2::LV aneurysm}}. #HKMLEtrap #ECG #Timing #Complication

146. LV aneurysm complicates {{c1::3-15%}} of large transmural MIs, most commonly in the {{c2::anterior-apical (LAD)}} territory. #CutOff #Complication #ACS

147. The three main complications of LV aneurysm are {{c1::mural thrombus + embolism}}, {{c2::ventricular arrhythmias (VT/VF)}}, and {{c3::heart failure}}. #Complication #ACS

148. A true LV aneurysm carries a {{c1::low}} risk of rupture compared to a pseudoaneurysm. #HKMLEtrap #Complication #ACS

--- MURAL THROMBUS ---

149. Large anterior MI is complicated by mural thrombus in up to {{c1::20%}} of cases. #CutOff #Complication #ACS

150. Mural thrombus forms most commonly in the first {{c1::2 weeks}} post-MI. #Timing #Complication #ACS

151. The most feared complication of mural thrombus is {{c1::cardioembolic stroke}}. #Complication #ACS

152. Investigation of choice for mural thrombus is {{c1::echocardiography with contrast agent}} (gold standard); {{c2::cardiac MRI}} has highest sensitivity. #Investigation #Complication #ACS

153. Treatment of mural thrombus requires {{c1::full anticoagulation}} (warfarin INR 2-3, or NOAC) — DAPT alone is {{c2::insufficient}}. #HKMLEtrap #Management #Complication #ACS

154. Duration of anticoagulation for mural thrombus is {{c1::3-6 months}} or until echo confirms thrombus resolution. #Management #CutOff #Complication #ACS

155. Mural thrombus formation is explained by Virchow's triad: {{c1::endothelial damage}} (necrotic endocardium), {{c2::stasis}} (akinetic wall), and {{c3::hypercoagulability}} (post-MI acute phase). #ACS #Complication

--- DRUG TRAPS ---

156. GTN must not be given to a patient who took sildenafil within {{c1::24 hours}} or tadalafil within {{c2::48 hours}}. #HKMLEtrap #Contraindication #Management #ACS

157. Aspirin's antiplatelet effect is reduced if the patient concurrently takes {{c1::ibuprofen}}, which competitively inhibits {{c2::COX-1 binding}}. #HKMLEtrap #Management #ACS

158. Beta-blockers are contraindicated in acute ACS complicated by {{c1::cardiogenic shock or acute pulmonary oedema}} — start only when haemodynamically stable. #HKMLEtrap #Contraindication #Management #ACS

159. Digoxin is absolutely contraindicated in {{c1::Wolff-Parkinson-White (WPW) syndrome + atrial fibrillation}} because it {{c2::accelerates accessory pathway conduction → VF}}. #HKMLEtrap #Contraindication

160. Non-aspirin NSAIDs (ibuprofen, diclofenac, naproxen) should be avoided post-MI because they {{c1::increase cardiovascular events and impair infarct healing}}. #HKMLEtrap #Contraindication #Management #ACS

161. In cocaine-induced MI, beta-blockers should be {{c1::avoided}} due to risk of {{c2::unopposed alpha-adrenergic stimulation causing coronary vasospasm}}. #HKMLEtrap #Contraindication #ACS

--- MNEMONICS (HIGH-YIELD LISTS) ---

162. Mnemonic for acute ACS management: {{c1::BATMAN}} = Beta-blocker, Aspirin, Thienopyridine, Morphine (caution), Anticoagulant, Nitrate. #Management #ACS

163. Mnemonic for post-MI secondary prevention: {{c1::ABCDE}} = Aspirin+ACEi, Beta-blocker, Cholesterol (statin), DAPT+Diabetes, Exercise+Eplerenone. #Management #ACS

164. Mnemonic for high-risk NSTEMI requiring invasive <2h strategy: {{c1::SHOCK STAR}} = Shock, HF, Ongoing ischaemia, CHB, Katastrophic complication, ST aVR, Troponin high, Arrhythmia, Recurrent ECG changes. #Management #ACS

165. Mnemonic for absolute contraindications to thrombolysis: {{c1::HBAS-NO}} = Haemorrhagic stroke, Bleeding, Aortic dissection, Severe HTN, Neurosurgery, Ongoing bleed. #Contraindication #Management #ACS

166. Mnemonic for signs of successful reperfusion: {{c1::STAR}} = ST resolution >50%, Troponin early peak, AIVR (reperfusion arrhythmia), Relief of pain. #Management #ACS

167. Mnemonic for post-MI complications overview: {{c1::PATCH-VALVE}} = Pulseless VF, Arrhythmias, Cardiogenic shock, Tamponade, Haemopericardium, VSD, Aneurysm, LVF, Valve (MR), Embolism. #Complication #ACS

168. Mnemonic for non-ACS causes of troponin elevation: {{c1::HEART FAILURE MAPS}} = HF, Endocarditis, Arrhythmias, RV strain, Takotsubo, Failure (renal), Anaemia, ICH (stroke), Lightning, Undergoing surgery, Rhabdomyolysis, Endurance, Myocarditis, Aortic dissection, Pneumonitis/Sepsis. #Investigation #HKMLEtrap #ACS

169. Mnemonic for causes of stable angina: {{c1::CASH BAD}} = CAD, Aortic stenosis, Spasm, HCM, Bridging, Anaemia, Dysfunctional endothelium. #ACS

170. Mnemonic for Beck's triad of cardiac tamponade: {{c1::HMJ}} = Hypotension, Muffled heart sounds, JVP raised. #Complication #ACS

============================================================
Total cards: 170
============================================================

python3 -c " from pypdf import PdfReader import os # Check if it's the same file…

mkdir -p /home/daytona/workspace/hkmle-acs && ls /home/daytona/workspace/hkmle-a…

~/hkmle-acs/mcq_generator.js

const {
  Document, Packer, Paragraph, TextRun, HeadingLevel,
  AlignmentType, BorderStyle, Table, TableRow, TableCell,
  WidthType, ShadingType, PageBreak
} = require('docx');
const fs = require('fs');

// ─── colour palette ────────────────────────────────────────────────────────────
const TEAL   = "1A6B72";   // headings / section banners
const GOLD   = "C8860A";   // correct answer label
const RED_BG = "FFF0F0";   // incorrect reasoning background
const GRN_BG = "F0FFF4";   // correct answer background
const GREY   = "F5F5F5";   // question vignette background
const WHITE  = "FFFFFF";

// ─── helper: coloured shaded paragraph ─────────────────────────────────────────
function shadedPara(text, bg, bold = false, color = "000000") {
  return new Paragraph({
    shading: { type: ShadingType.CLEAR, fill: bg },
    spacing: { before: 40, after: 40 },
    indent: { left: 120, right: 120 },
    children: [new TextRun({ text, bold, color, size: 20 })],
  });
}

function heading1(text) {
  return new Paragraph({
    heading: HeadingLevel.HEADING_1,
    spacing: { before: 360, after: 120 },
    shading: { type: ShadingType.CLEAR, fill: TEAL },
    children: [new TextRun({ text, bold: true, color: WHITE, size: 28 })],
  });
}

function heading2(text) {
  return new Paragraph({
    heading: HeadingLevel.HEADING_2,
    spacing: { before: 300, after: 100 },
    children: [new TextRun({ text, bold: true, color: TEAL, size: 24 })],
  });
}

function plain(text, bold = false, size = 20) {
  return new Paragraph({
    spacing: { before: 60, after: 60 },
    children: [new TextRun({ text, bold, size })],
  });
}

function optionPara(letter, text, isCorrect) {
  const bg = isCorrect ? GRN_BG : WHITE;
  const bold = isCorrect;
  const prefix = isCorrect ? `✓ ${letter}. ` : `${letter}. `;
  return new Paragraph({
    shading: { type: ShadingType.CLEAR, fill: bg },
    spacing: { before: 40, after: 40 },
    indent: { left: 240 },
    children: [
      new TextRun({ text: prefix, bold: true, color: isCorrect ? "1E7A34" : "000000", size: 20 }),
      new TextRun({ text, bold, size: 20 }),
    ],
  });
}

function answerBox(correct, explanation) {
  return new Paragraph({
    shading: { type: ShadingType.CLEAR, fill: GRN_BG },
    spacing: { before: 80, after: 80 },
    indent: { left: 120, right: 120 },
    children: [
      new TextRun({ text: `CORRECT ANSWER: ${correct}   `, bold: true, color: "1E7A34", size: 20 }),
      new TextRun({ text: explanation, size: 20 }),
    ],
  });
}

function whyNotLine(letter, text) {
  return new Paragraph({
    shading: { type: ShadingType.CLEAR, fill: RED_BG },
    spacing: { before: 30, after: 30 },
    indent: { left: 240, right: 120 },
    children: [
      new TextRun({ text: `Why not ${letter}: `, bold: true, color: "8B0000", size: 19 }),
      new TextRun({ text, size: 19 }),
    ],
  });
}

function tagLine(tag) {
  return new Paragraph({
    spacing: { before: 60, after: 120 },
    children: [new TextRun({ text: `[TAG: ${tag}]`, italics: true, color: "555555", size: 18 })],
  });
}

function divider() {
  return new Paragraph({
    spacing: { before: 160, after: 160 },
    border: { bottom: { style: BorderStyle.SINGLE, size: 4, color: TEAL } },
    children: [new TextRun({ text: "" })],
  });
}

// ═══════════════════════════════════════════════════════════════════════════════
// MCQ DATA
// ═══════════════════════════════════════════════════════════════════════════════
const questions = [
// ── SECTION 1: DIAGNOSIS & SPECTRUM ──────────────────────────────────────────
{
  section: "SECTION 1: DIAGNOSIS & SPECTRUM",
  num: 1,
  stem: "A 58-year-old man presents to the emergency department with a 45-minute history of central crushing chest pain radiating to his left arm. He is diaphoretic and nauseated. His BP is 138/86 mmHg, HR 96 bpm, SpO2 98% on room air. ECG shows 2mm ST depression in leads V4–V6 with deep T-wave inversion. Serial troponin at 0 hours is 0.08 ng/mL (ULN 0.04) and rises to 0.22 ng/mL at 3 hours. What is the most likely diagnosis?",
  options: { A:"Unstable angina", B:"STEMI", C:"NSTEMI", D:"Aortic dissection", E:"Pulmonary embolism" },
  correct: "C",
  explanation: "Rising troponin (0.08→0.22) with ST depression and no persistent ST elevation defines NSTEMI. The kinetic rise confirms acute myocardial necrosis.",
  whyNot: {
    A:"Unstable angina has identical ECG changes but troponin remains normal.",
    B:"STEMI requires persistent ST elevation ≥1mm in ≥2 contiguous leads; ST depression here indicates subendocardial injury.",
    D:"Aortic dissection typically presents with tearing back pain, unequal blood pressures, and widened mediastinum.",
    E:"PE may cause troponin rise and right heart strain (S1Q3T3), not V4–V6 ST depression.",
  },
  tag: "Diagnosis",
},
{
  section: null,
  num: 2,
  stem: "A 62-year-old woman with hypertension and type 2 diabetes presents with 3 hours of epigastric discomfort, nausea, and diaphoresis. She denies chest pain. BP is 145/90 mmHg, HR 88 bpm. ECG shows new ST elevation of 2mm in leads II, III, and aVF, with reciprocal ST depression in leads I and aVL. What is the most likely diagnosis?",
  options: { A:"Acute pancreatitis", B:"Peptic ulcer perforation", C:"Inferior STEMI", D:"Anterior STEMI", E:"Pericarditis" },
  correct: "C",
  explanation: "ST elevation in II, III, aVF with reciprocal changes in I and aVL is the classic pattern of inferior STEMI. Diabetic and female patients frequently present atypically with epigastric pain.",
  whyNot: {
    A:"Acute pancreatitis does not produce ST elevation; lipase/amylase would be elevated.",
    B:"Perforation causes peritonism and free air on X-ray; no ECG changes.",
    D:"Anterior STEMI shows ST elevation in V1–V4, not inferior leads.",
    E:"Pericarditis shows diffuse saddle-shaped ST elevation with PR depression, not territorial changes with reciprocal depression.",
  },
  tag: "Diagnosis",
},
{
  section: null,
  num: 3,
  stem: "A 70-year-old man presents with 30 minutes of central chest pain. ECG shows ST depression of 1.5mm in V1 and V2 with tall, broad R waves in V1 (R:S ratio >1) and upright T waves in V1–V2. There is also 2mm ST elevation in lead III. What is the most appropriate next investigation?",
  options: { A:"Repeat ECG in 30 minutes", B:"CT pulmonary angiography", C:"Posterior ECG leads V7–V9", D:"Right-sided ECG leads (V4R)", E:"Transthoracic echocardiogram" },
  correct: "C",
  explanation: "ST depression in V1–V2 with tall R waves and upright T waves is the classic pattern of posterior MI. Posterior leads V7–V9 must be obtained — ST elevation ≥0.5mm confirms posterior STEMI and mandates urgent reperfusion.",
  whyNot: {
    A:"Delaying in a likely posterior MI wastes critical reperfusion time.",
    B:"CTPA is for suspected PE, which would show right heart strain, not posterior ST changes.",
    D:"Right-sided leads are for suspected RV infarction; this pattern points to posterior MI.",
    E:"Echo does not confirm posterior STEMI territory needed to trigger the cath lab.",
  },
  tag: "Investigation",
},
{
  section: null,
  num: 4,
  stem: "A 55-year-old man with hypertension presents with acute chest pain of 1-hour duration. ECG shows a new left bundle branch block (LBBB). Troponin at 0 hours is within normal range. What is the most appropriate immediate management?",
  options: { A:"Admit for serial troponins and repeat ECG at 3 hours", B:"Apply Sgarbossa criteria; if score ≥3, activate the catheterisation laboratory", C:"Discharge with outpatient stress testing in 72 hours", D:"Administer thrombolysis immediately", E:"Obtain CT coronary angiography" },
  correct: "B",
  explanation: "New LBBB with acute chest pain is a STEMI equivalent. Sgarbossa criteria should be applied; a score ≥3 warrants immediate cath lab activation. A normal 0-hour troponin does not exclude early STEMI.",
  whyNot: {
    A:"Serial troponins alone are inappropriate — if LBBB is truly new and criteria are met, reperfusion delay increases mortality.",
    C:"Discharge is dangerous in new LBBB with acute chest pain.",
    D:"Thrombolysis without confirming MI in LBBB risks unnecessary haemorrhagic complications; primary PCI is preferred.",
    E:"CTCA delays definitive reperfusion — not appropriate in the acute STEMI pathway.",
  },
  tag: "Emergency",
},
{
  section: null,
  num: 5,
  stem: "A 48-year-old male cocaine user presents at 3 AM with severe chest pain at rest. ECG shows transient ST elevation in V2–V4 that resolves within 10 minutes. Troponin at 0 hours and 3 hours is negative. Coronary angiography shows smooth coronary arteries with no obstructive disease. What is the most likely diagnosis?",
  options: { A:"NSTEMI", B:"Type 2 MI", C:"Prinzmetal (vasospastic) angina", D:"Unstable angina", E:"Hypertrophic cardiomyopathy" },
  correct: "C",
  explanation: "Transient ST elevation at rest, normal troponin, normal coronary anatomy, and cocaine use is classic Prinzmetal/vasospastic angina. Cocaine causes intense epicardial vasospasm.",
  whyNot: {
    A:"NSTEMI requires troponin elevation.",
    B:"Type 2 MI involves supply-demand mismatch; troponin would usually rise.",
    D:"Unstable angina would show a plaque-based mechanism; normal coronaries exclude this.",
    E:"HCM does not cause transient ST elevation resolving within minutes at rest.",
  },
  tag: "Diagnosis",
},
// ── SECTION 2: ECG INTERPRETATION ────────────────────────────────────────────
{
  section: "SECTION 2: ECG INTERPRETATION",
  num: 6,
  stem: "A 67-year-old woman with inferior STEMI undergoes primary PCI. Immediately after balloon inflation her ECG shows a regular wide-complex rhythm at 75 bpm with P waves dissociated from the QRS. She is haemodynamically stable (BP 118/72 mmHg) and asymptomatic. What is the most appropriate management?",
  options: { A:"Administer IV amiodarone 300mg immediately", B:"Perform DC cardioversion at 200J", C:"Administer IV atropine 0.5mg", D:"Observe — this is a benign reperfusion arrhythmia", E:"Insert a temporary transvenous pacemaker" },
  correct: "D",
  explanation: "Accelerated idioventricular rhythm (AIVR) — wide-complex rhythm 60–120 bpm with AV dissociation — is a classic benign reperfusion arrhythmia requiring no treatment.",
  whyNot: {
    A:"Amiodarone is for haemodynamically unstable VT; AIVR is not malignant.",
    B:"DC cardioversion is for haemodynamically unstable tachyarrhythmias; this patient is stable.",
    C:"Atropine is for symptomatic bradycardia; AIVR is not bradycardia.",
    E:"Pacing is for complete heart block with haemodynamic compromise, not AIVR.",
  },
  tag: "Emergency",
},
{
  section: null,
  num: 7,
  stem: "A 60-year-old man with anterior STEMI is on day 2 in the coronary care unit. His ECG shows progressive PR prolongation over several beats, followed by a dropped QRS complex, then the cycle repeats. BP is 122/78 mmHg, HR 52 bpm, and he is asymptomatic. What does this ECG finding indicate?",
  options: { A:"Mobitz Type II block — urgent temporary pacing required", B:"Mobitz Type I (Wenckebach) block — usually benign, observe", C:"Third-degree complete heart block — urgent temporary pacing required", D:"First-degree heart block — no action needed", E:"Bifascicular block — elective pacemaker in 48 hours" },
  correct: "B",
  explanation: "Progressive PR prolongation then dropped beat = Mobitz Type I (Wenckebach). In a haemodynamically stable patient this is observed; urgent pacing is not needed.",
  whyNot: {
    A:"Mobitz Type II shows fixed PR interval with sudden dropped beats and carries poor prognosis requiring pacing.",
    C:"Complete heart block shows complete PR dissociation, not progressive prolongation.",
    D:"First-degree block is prolonged PR with no dropped beats.",
    E:"Bifascicular block = RBBB + left axis deviation; not described here.",
  },
  tag: "Interpretation",
},
{
  section: null,
  num: 8,
  stem: "A 65-year-old man presents with 2 hours of central chest pain. ECG shows diffuse ST elevation in leads I, II, III, aVF, aVL, V2–V6, with PR segment depression in multiple leads. There are no reciprocal ST changes. What is the most likely diagnosis?",
  options: { A:"Anterior STEMI", B:"Left main stem occlusion", C:"Pericarditis", D:"Hyperkalaemia", E:"Takotsubo cardiomyopathy" },
  correct: "C",
  explanation: "Diffuse (pan-lead) ST elevation with PR depression and absent reciprocal changes is classic acute pericarditis. STEMI produces territorial ST elevation with reciprocal changes.",
  whyNot: {
    A:"Anterior STEMI produces ST elevation limited to V1–V4 with reciprocal inferior changes.",
    B:"Left main stem occlusion produces diffuse ST depression with ST elevation in aVR — not generalised ST elevation.",
    D:"Hyperkalaemia produces peaked T waves, wide QRS, and sinusoidal pattern.",
    E:"Takotsubo shows T-wave inversion and QTc prolongation in V4–V6, not pan-lead ST elevation.",
  },
  tag: "Interpretation",
},
{
  section: null,
  num: 9,
  stem: "A 72-year-old man is admitted with chest pain. ECG shows ST elevation in II, III, aVF, and right-sided lead V4R. BP is 82/50 mmHg with markedly elevated JVP. Lung fields are clear on auscultation. What is the most appropriate immediate fluid management?",
  options: { A:"Furosemide 40mg IV", B:"IV morphine and GTN infusion", C:"IV normal saline fluid challenge 500mL", D:"GTN infusion at 50 mcg/min", E:"IV metoprolol 5mg" },
  correct: "C",
  explanation: "V4R ST elevation indicates right ventricular infarction. RV infarction is preload-dependent: treatment requires IV fluid loading. GTN and diuretics reduce preload and are catastrophic.",
  whyNot: {
    A:"Furosemide reduces preload — catastrophic in RV infarction.",
    B:"GTN is absolutely contraindicated in RV infarction.",
    D:"GTN infusion — same contraindication; will worsen hypotension fatally.",
    E:"Beta-blockers contraindicated in acute hypotension/cardiogenic shock.",
  },
  tag: "Emergency",
},
// ── SECTION 3: RISK STRATIFICATION ───────────────────────────────────────────
{
  section: "SECTION 3: RISK STRATIFICATION",
  num: 10,
  stem: "A 64-year-old woman with hypertension, diabetes, and hyperlipidaemia presents with two episodes of rest chest pain in the past 24 hours. ECG shows 1.5mm ST depression in V4–V5. Troponin at 0 hours is 0.06 ng/mL (ULN 0.04) and rises to 0.18 ng/mL at 3 hours. She has used aspirin daily for 5 years. What is the minimum TIMI score in this patient?",
  options: { A:"2", B:"3", C:"4", D:"5", E:"6" },
  correct: "D",
  explanation: "TIMI criteria met: ≥3 risk factors (1), ST deviation (1), ≥2 anginal events in 24h (1), aspirin use in 7 days (1), elevated markers (1) = 5. Age 64 does not meet the ≥65 threshold.",
  whyNot: {
    A:"Score of 2 underestimates — five criteria are clearly met.",
    B:"Score of 3 is too low.",
    C:"Score of 4 misses one criterion present.",
    E:"Score of 6 would require age ≥65; she is 64.",
  },
  tag: "CutOff",
},
{
  section: null,
  num: 11,
  stem: "A 71-year-old man with NSTEMI has a GRACE score of 155. He is haemodynamically stable (BP 126/80 mmHg, HR 82 bpm) with significantly elevated and dynamic troponin. No mechanical complications are present. What is the recommended timing for coronary angiography per ESC 2023 guidelines?",
  options: { A:"Within 2 hours", B:"Within 24 hours", C:"Within 72 hours", D:"Within 1 week", E:"Ischaemia-guided strategy only if symptoms recur" },
  correct: "B",
  explanation: "GRACE >140 indicates high risk (in-hospital mortality >3%). ESC 2023 recommends early invasive strategy within 24 hours. The <2h strategy is reserved for very high-risk features (cardiogenic shock, refractory ischaemia).",
  whyNot: {
    A:"<2h applies to very high-risk features like cardiogenic shock; this patient is haemodynamically stable.",
    C:"<72h applies to intermediate risk (GRACE 109–140).",
    D:"One week is inappropriate for high-risk NSTEMI.",
    E:"Conservative strategy is appropriate only for low-risk NSTEMI (GRACE <109).",
  },
  tag: "Management",
},
// ── SECTION 4: ACUTE MANAGEMENT ──────────────────────────────────────────────
{
  section: "SECTION 4: ACUTE MANAGEMENT",
  num: 12,
  stem: "A 59-year-old man with anterior STEMI is being prepared for primary PCI. Aspirin 300mg has been given. Which P2Y12 inhibitor is the preferred loading agent?",
  options: { A:"Clopidogrel 75mg", B:"Prasugrel 60mg", C:"Ticagrelor 180mg", D:"Clopidogrel 300mg", E:"Aspirin 300mg (second dose)" },
  correct: "C",
  explanation: "Ticagrelor 180mg is the preferred P2Y12 inhibitor in ACS — superior to clopidogrel in the PLATO trial, reducing CV death, MI, stroke, and all-cause mortality.",
  whyNot: {
    A:"Clopidogrel 75mg is the maintenance dose; also not first-line in ACS.",
    B:"Prasugrel 60mg is a valid alternative but not the preferred first-line choice.",
    D:"Clopidogrel 300mg is acceptable but inferior to ticagrelor per PLATO.",
    E:"Double-dosing aspirin provides no additional antiplatelet benefit.",
  },
  tag: "Management",
},
{
  section: null,
  num: 13,
  stem: "A 68-year-old man with STEMI is haemodynamically stable (BP 134/82 mmHg, HR 90 bpm). He reports taking sildenafil 6 hours ago. He has severe chest pain. Which medication is contraindicated at this time?",
  options: { A:"Aspirin", B:"Ticagrelor", C:"GTN (glyceryl trinitrate)", D:"Enoxaparin", E:"Metoprolol" },
  correct: "C",
  explanation: "GTN is absolutely contraindicated within 24 hours of sildenafil use. Both cause NO-mediated vasodilation; the combination causes profound, potentially fatal hypotension.",
  whyNot: {
    A:"Aspirin has no interaction with sildenafil.",
    B:"Ticagrelor has no interaction with sildenafil; it is indicated.",
    D:"Enoxaparin has no sildenafil interaction.",
    E:"Metoprolol is appropriate if haemodynamically stable; no sildenafil interaction.",
  },
  tag: "Contraindication",
},
{
  section: null,
  num: 14,
  stem: "A 74-year-old woman with NSTEMI is commenced on clopidogrel. She has a peptic ulcer history requiring gastroprotection. Which PPI should be prescribed to minimise the interaction with clopidogrel?",
  options: { A:"Omeprazole", B:"Esomeprazole", C:"Lansoprazole", D:"Pantoprazole", E:"Rabeprazole" },
  correct: "D",
  explanation: "Pantoprazole has the least inhibitory effect on CYP2C19. Clopidogrel requires CYP2C19 for activation; omeprazole and esomeprazole significantly reduce this, diminishing antiplatelet efficacy.",
  whyNot: {
    A:"Omeprazole is the most potent CYP2C19 inhibitor — highest risk of reducing clopidogrel efficacy.",
    B:"Esomeprazole (S-enantiomer of omeprazole) also significantly inhibits CYP2C19.",
    C:"Lansoprazole has moderate CYP2C19 inhibition.",
    E:"Rabeprazole has less inhibition than omeprazole but pantoprazole is still the safest choice.",
  },
  tag: "DrugInteraction",
},
{
  section: null,
  num: 15,
  stem: "A 63-year-old man with STEMI is admitted to a hospital without cardiac catheterisation facilities. The nearest PCI centre is 3 hours away. He has been symptomatic for 90 minutes. BP 152/94 mmHg, HR 88 bpm, SpO2 98%. No prior stroke or active bleeding. What is the most appropriate reperfusion strategy?",
  options: { A:"Transfer immediately for primary PCI — it is always superior", B:"Administer thrombolysis now, then transfer for angiography in 3–24 hours", C:"Administer streptokinase and repeat in 4 hours if pain persists", D:"Transfer for primary PCI but administer IABP first", E:"Medical management only with DAPT and anticoagulation" },
  correct: "B",
  explanation: "When primary PCI cannot be achieved within 120 minutes of FMC, fibrinolysis should be given immediately. After successful thrombolysis, transfer for angiography within 3–24 hours (pharmacoinvasive strategy).",
  whyNot: {
    A:"Primary PCI is superior only when deliverable within 120 minutes; a 3-hour transfer exceeds this.",
    C:"Repeat streptokinase is contraindicated — antibody formation causes anaphylaxis.",
    D:"IABP is not indicated for haemodynamically stable STEMI before thrombolysis.",
    E:"Medical management alone for STEMI without reperfusion has unacceptably high mortality.",
  },
  tag: "Emergency",
},
{
  section: null,
  num: 16,
  stem: "A 66-year-old woman is brought with a 2-hour anterior STEMI. She had a haemorrhagic stroke 8 months ago. Primary PCI is available within 60 minutes. What is the most appropriate management?",
  options: { A:"Administer tenecteplase immediately", B:"Proceed with primary PCI", C:"Administer alteplase at a reduced dose", D:"Administer streptokinase as it carries lower bleeding risk", E:"Medical management with aspirin and anticoagulation only" },
  correct: "B",
  explanation: "Prior haemorrhagic stroke is an absolute contraindication to all thrombolytics at any time. It is NOT a contraindication to primary PCI. PCI is available within 60 minutes — the correct and only reperfusion option.",
  whyNot: {
    A:"Haemorrhagic stroke (ever) is an absolute contraindication to all thrombolytics.",
    C:"No dose of thrombolytic is safe with prior haemorrhagic stroke.",
    D:"Streptokinase carries the same contraindication; prior haemorrhagic stroke prohibits all thrombolytics.",
    E:"Medical management alone for a 2-hour anterior STEMI when PCI is available is inappropriate.",
  },
  tag: "Contraindication",
},
{
  section: null,
  num: 17,
  stem: "A 57-year-old man with STEMI receives morphine while awaiting primary PCI. The anaesthetist notes that morphine may interact with the P2Y12 inhibitor loading dose given 20 minutes ago. What is the mechanism of this concern?",
  options: { A:"Morphine inhibits CYP2C19 reducing clopidogrel activation", B:"Morphine delays gastric emptying, reducing oral antiplatelet absorption", C:"Morphine causes coronary vasospasm opposing antiplatelet effect", D:"Morphine increases hepatic metabolism of ticagrelor", E:"Morphine inhibits platelet GpIIb/IIIa directly" },
  correct: "B",
  explanation: "Morphine delays gastric emptying and reduces GI motility, slowing absorption of orally administered antiplatelet agents, resulting in lower peak plasma concentrations and delayed antiplatelet effect.",
  whyNot: {
    A:"Morphine does not inhibit CYP2C19.",
    C:"Morphine does not cause coronary vasospasm; this is a cocaine effect.",
    D:"Morphine does not increase hepatic metabolism of ticagrelor.",
    E:"Morphine has no direct platelet GpIIb/IIIa inhibitory effect.",
  },
  tag: "DrugInteraction",
},
{
  section: null,
  num: 18,
  stem: "A 61-year-old man is admitted with anterior STEMI. SpO2 is 97% on room air. A nurse initiates high-flow oxygen at 10L/min via non-rebreather mask. What is the main concern with this action?",
  options: { A:"Oxygen accelerates atherosclerotic plaque rupture", B:"High-flow oxygen causes tachycardia, increasing myocardial demand", C:"Hyperoxia causes coronary vasoconstriction and may increase infarct size", D:"Oxygen inhibits the fibrinolytic system, promoting thrombus extension", E:"Oxygen interacts with heparin, reducing its anticoagulant effect" },
  correct: "C",
  explanation: "Supplemental oxygen in normoxic ACS patients (SpO2 ≥94%) is harmful. Hyperoxia causes coronary vasoconstriction and oxidative stress, which can increase infarct size. O2 is only indicated if SpO2 <94%.",
  whyNot: {
    A:"Hyperoxia does not acutely rupture plaques.",
    B:"Oxygen does not cause tachycardia at standard flow rates.",
    D:"Oxygen does not inhibit fibrinolysis.",
    E:"There is no oxygen-heparin interaction.",
  },
  tag: "Management",
},
// ── SECTION 5: BIOMARKERS & INVESTIGATIONS ────────────────────────────────────
{
  section: "SECTION 5: BIOMARKERS & INVESTIGATIONS",
  num: 19,
  stem: "A 53-year-old man arrives at 8 AM with chest pain that began at 6 AM. His hs-TnT at 0 hours is 3 ng/L (ULN 14 ng/L). He is pain-free and ECG shows no acute changes. What is the most appropriate next step using the ESC 0h/1h algorithm?",
  options: { A:"Rule in MI — hs-TnT is elevated; admit for angiography", B:"Rule out MI — value is below 5 ng/L; discharge safely", C:"Repeat hs-TnT at 1 hour and assess for change ≥6 ng/L (rule-in) or <4 ng/L change (confirm rule-out)", D:"Repeat hs-TnT at 3 hours as the 0h value is indeterminate", E:"Proceed immediately to stress echocardiography" },
  correct: "C",
  explanation: "The ESC 0h/1h algorithm requires the 1-hour sample to confirm rule-out (<4 ng/L change) or identify a rising pattern (≥6 ng/L change). The 0h value alone at 3 ng/L is insufficient to discharge without the 1h repeat.",
  whyNot: {
    A:"hs-TnT of 3 ng/L is below the ULN; 'elevated' does not apply.",
    B:"Premature rule-out — the 1h repeat is required to confirm the change criterion.",
    D:"The 0h/1h algorithm replaces the 0h/3h algorithm; 3h is the fallback for intermediate results.",
    E:"Stress echo is appropriate after ACS is ruled out, not during the acute evaluation period.",
  },
  tag: "Investigation",
},
{
  section: null,
  num: 20,
  stem: "A 69-year-old man had a large anterior STEMI 10 days ago. He re-presents with 1 hour of severe chest pain. ECG shows new ST elevation in V1–V4. His troponin was 0.92 ng/mL on day 3 and was declining. Today's troponin is 0.09 ng/mL. Which biomarker would BEST confirm reinfarction?",
  options: { A:"hs-Troponin I repeated at 3 hours", B:"LDH", C:"Myoglobin", D:"CK-MB", E:"BNP" },
  correct: "D",
  explanation: "CK-MB is preferred for detecting reinfarction because it returns to normal within 48–72 hours post-MI. A new CK-MB rise after returning to baseline confirms reinfarction. Troponin remains elevated 5–14 days making a new rise unreliable in this window.",
  whyNot: {
    A:"Troponin remains elevated for up to 14 days post-MI — a new rise may be persistent elevation.",
    B:"LDH remains elevated for 8–14 days; useless for acute reinfarction diagnosis.",
    C:"Myoglobin is non-specific and has poor diagnostic value.",
    E:"BNP reflects ventricular wall stress and heart failure, not myocyte necrosis.",
  },
  tag: "Investigation",
},
{
  section: null,
  num: 21,
  stem: "A 78-year-old woman with stage 3B CKD (eGFR 32 mL/min) is admitted with chest pain. Her hs-TnT is 68 ng/L (ULN 14 ng/L). ECG shows no ST changes. She is mildly dyspnoeic but otherwise asymptomatic. What is the most appropriate interpretation of this result?",
  options: { A:"Confirms Type 1 MI — urgent coronary angiography", B:"Confirms Type 2 MI due to reduced O2 delivery in CKD", C:"Elevated troponin in CKD may reflect chronic myocardial injury; serial measurement and clinical correlation required", D:"Troponin is unreliable in CKD and should not be used", E:"The threshold in CKD is double the normal ULN, so this result is normal" },
  correct: "C",
  explanation: "CKD impairs troponin clearance causing chronic elevation. A single elevated troponin in CKD does not confirm ACS. Serial measurement (dynamic rise >20%) combined with clinical context, symptoms, and ECG distinguishes acute MI from chronic elevation.",
  whyNot: {
    A:"A single troponin without rise/fall kinetics in CKD does not confirm Type 1 MI.",
    B:"CKD alone without a precipitating stress does not constitute Type 2 MI.",
    D:"Troponin is still recommended in CKD; it requires careful interpretation.",
    E:"There is no validated 'double ULN' adjustment for CKD.",
  },
  tag: "Interpretation",
},
// ── SECTION 6: POST-MI COMPLICATIONS ─────────────────────────────────────────
{
  section: "SECTION 6: POST-MI COMPLICATIONS",
  num: 22,
  stem: "A 64-year-old man on day 5 post-anterior STEMI develops sudden dyspnoea and haemodynamic deterioration. Examination reveals a new loud holosystolic murmur at the left lower sternal border with a parasternal thrill. BP 84/50 mmHg, SpO2 88%. What is the most appropriate immediate investigation?",
  options: { A:"CT pulmonary angiography", B:"12-lead ECG", C:"Right heart catheterisation (Swan-Ganz)", D:"Bedside transthoracic echocardiography with colour flow Doppler", E:"Chest X-ray" },
  correct: "D",
  explanation: "New holosystolic murmur at the left sternal border on day 5 post-STEMI with haemodynamic collapse = post-MI VSD until proven otherwise. Bedside echo with colour flow Doppler provides immediate visualisation of the defect and L→R shunt.",
  whyNot: {
    A:"CTPA is for suspected PE; this is a mechanical complication of MI.",
    B:"ECG confirms old STEMI but cannot diagnose VSD.",
    C:"Swan-Ganz is invasive and slower than echo as first investigation.",
    E:"CXR shows pulmonary oedema but cannot diagnose VSD.",
  },
  tag: "NextBestStep",
},
{
  section: null,
  num: 23,
  stem: "A 61-year-old woman on day 4 post-inferior STEMI develops sudden haemodynamic collapse. A new loud holosystolic murmur is heard at the apex, radiating to the axilla. Swan-Ganz catheterisation shows PCWP 28 mmHg with large V waves, cardiac output 2.1 L/min. O2 saturation in the right atrium and right ventricle are 68% and 69% respectively. What is the most likely diagnosis?",
  options: { A:"Post-MI ventricular septal defect", B:"Post-MI free wall rupture with tamponade", C:"Post-MI acute mitral regurgitation due to papillary muscle rupture", D:"Post-MI right ventricular infarction", E:"Flash pulmonary oedema from LV systolic failure" },
  correct: "C",
  explanation: "Large V waves on PCWP indicate acute MR (retrograde LA filling during systole). Absent O2 step-up from RA to RV excludes VSD. Apical murmur radiating to axilla + inferior MI = posterior papillary muscle rupture (single RCA supply).",
  whyNot: {
    A:"VSD shows significant O2 step-up RA→RV (>8%); absent here.",
    B:"Free wall rupture causes tamponade physiology (pressure equalisation, no new murmur).",
    D:"RV infarction causes hypotension with clear lungs and elevated JVP but no loud apical murmur.",
    E:"Flash pulmonary oedema from LV failure would not produce large V waves without MR.",
  },
  tag: "Diagnosis",
},
{
  section: null,
  num: 24,
  stem: "A 70-year-old man had a large anterior STEMI 4 days ago treated with thrombolysis. He develops sudden chest pain, then becomes pulseless. ECG shows organised electrical activity. Bedside echo shows pericardial effusion with RV diastolic collapse. What is the most appropriate immediate action?",
  options: { A:"Administer IV adrenaline 1mg and continue CPR", B:"Defibrillation at 200J", C:"Pericardiocentesis", D:"IV atropine 1mg", E:"Thrombolysis with alteplase" },
  correct: "C",
  explanation: "PEA in a post-STEMI patient + echo showing tamponade = left ventricular free wall rupture. Emergency pericardiocentesis is the immediate life-saving bridge, followed by definitive emergency surgery.",
  whyNot: {
    A:"Adrenaline alone will not restore output in tamponade — the mechanical obstruction must be relieved.",
    B:"Defibrillation is for pulseless VT/VF; electrical activity is organised here.",
    D:"Atropine is for bradycardia/asystole, not PEA from tamponade.",
    E:"Thrombolysis would worsen haemopericardium; absolutely contraindicated in free wall rupture.",
  },
  tag: "Emergency",
},
{
  section: null,
  num: 25,
  stem: "A 66-year-old man on day 5 post-inferior STEMI develops sudden hypotension (BP 78/42 mmHg) and a new holosystolic murmur loudest at the apex with radiation to the axilla. Bedside echo shows a flail posterior mitral leaflet. Which papillary muscle has ruptured, and why is this more common in inferior MI?",
  options: { A:"Anterolateral — supplied solely by the LAD", B:"Posterior-medial — supplied solely by the RCA", C:"Anterolateral — supplied solely by the RCA", D:"Posterior-medial — supplied by both LAD and LCx", E:"Both papillary muscles equally — dual coronary supply" },
  correct: "B",
  explanation: "The posterior-medial papillary muscle has a single blood supply from the RCA only, making it uniquely vulnerable to ischaemia in RCA-territory inferior MI. The anterolateral has dual supply (LAD + LCx) which protects it.",
  whyNot: {
    A:"The anterolateral papillary muscle has dual supply (LAD + LCx), not sole LAD supply.",
    C:"The anterolateral is not supplied solely by the RCA.",
    D:"The posterior-medial muscle has single supply (RCA only), not dual supply.",
    E:"Papillary muscles do not have equal vulnerability.",
  },
  tag: "Diagnosis",
},
{
  section: null,
  num: 26,
  stem: "A 55-year-old man had a large anterior STEMI with primary PCI 6 days ago. He develops sudden PEA. Bedside ECG shows sinus rhythm. What is the single most important immediate next step?",
  options: { A:"Check electrolytes and administer IV potassium", B:"Administer IV adrenaline 1mg and continue CPR", C:"Perform bedside echocardiography", D:"Obtain 12-lead ECG", E:"Administer sodium bicarbonate 50mmol IV" },
  correct: "C",
  explanation: "PEA in a post-MI patient 3–7 days after MI = free wall rupture and cardiac tamponade until proven otherwise. Bedside echo identifies pericardial effusion/haemopericardium and directs immediate surgical management.",
  whyNot: {
    A:"Electrolyte correction without identifying the cause is not the priority.",
    B:"CPR alone will fail in tamponade without relieving the mechanical obstruction.",
    D:"ECG shows organised activity in PEA but does not identify the mechanical cause.",
    E:"Bicarbonate treats metabolic acidosis — not the primary intervention in mechanical PEA.",
  },
  tag: "NextBestStep",
},
{
  section: null,
  num: 27,
  stem: "A 67-year-old man presents 6 weeks post-STEMI with sharp pleuritic chest pain, fever (38.4°C), ESR 78 mm/hr, and negative troponin. Echo shows pericardial and small pleural effusion. ECG shows diffuse saddle-shaped ST elevation with PR depression. What is the most appropriate treatment?",
  options: { A:"Repeat primary PCI — this represents reinfarction", B:"High-dose corticosteroids (prednisolone 1mg/kg/day)", C:"NSAIDs (ibuprofen) plus colchicine", D:"Ibuprofen alone", E:"Aspirin alone" },
  correct: "C",
  explanation: "Fever, pleuritic chest pain, pleural effusion, elevated ESR, and negative troponin at 6 weeks = Dressler's syndrome. First-line: NSAIDs + colchicine. At 6 weeks the infarct is healed so NSAIDs are safe.",
  whyNot: {
    A:"Negative troponin excludes reinfarction; ECG pattern is pericarditis not STEMI.",
    B:"Corticosteroids are reserved for refractory Dressler's — not first-line.",
    D:"Ibuprofen alone without colchicine has higher recurrence rate.",
    E:"Aspirin alone is insufficient for Dressler's syndrome.",
  },
  tag: "Management",
},
{
  section: null,
  num: 28,
  stem: "A 60-year-old woman is on day 2 post-large anterior STEMI. She develops sharp positional chest pain worse when lying flat and better when sitting forward. A pericardial friction rub is heard. She is haemodynamically stable. What is the most appropriate management?",
  options: { A:"Ibuprofen 600mg TDS plus colchicine", B:"Aspirin 600mg TDS (increased dose) plus colchicine", C:"Prednisolone 1mg/kg/day", D:"Aspirin at the current post-MI dose plus colchicine", E:"Indomethacin 50mg TDS" },
  correct: "D",
  explanation: "Early post-MI pericarditis (day 2). Patient is already on aspirin post-MI — maintain it and add colchicine to reduce recurrence. Non-aspirin NSAIDs impair infarct healing.",
  whyNot: {
    A:"Ibuprofen impairs infarct healing and is contraindicated in early post-MI pericarditis.",
    B:"Increasing aspirin dose is unnecessary; adding colchicine to existing aspirin is the correct approach.",
    C:"Corticosteroids are absolutely contraindicated — they impair scar formation, risking rupture.",
    E:"Indomethacin impairs infarct healing — contraindicated here.",
  },
  tag: "Management",
},
{
  section: null,
  num: 29,
  stem: "A 72-year-old man is reviewed 10 weeks after a large anterior STEMI. ECG shows persistent 2mm ST elevation in V1–V4, also present at his 4-week review. No chest pain. Echo shows akinetic apical segment with no pericardial effusion. Troponin is negative. What is the most likely explanation?",
  options: { A:"Silent reinfarction", B:"Left ventricular aneurysm", C:"Dressler's syndrome", D:"Pericarditis", E:"Left main stem occlusion" },
  correct: "B",
  explanation: "Persistent ST elevation >2 weeks post-MI in the territory of the original infarct = LV aneurysm until proven otherwise. Echo confirming dyskinetic apex with no effusion supports this. Negative troponin excludes reinfarction.",
  whyNot: {
    A:"Reinfarction requires troponin elevation; troponin is negative.",
    C:"Dressler's presents with fever, pleuritic pain, raised ESR, and pericardial effusion.",
    D:"Pericarditis presents with symptoms, friction rub, and diffuse non-territorial ST changes.",
    E:"Left main stem occlusion presents as an acute catastrophic event.",
  },
  tag: "Diagnosis",
},
{
  section: null,
  num: 30,
  stem: "A 64-year-old man had a large anterior STEMI 8 days ago. Echo shows a 2cm thrombus in the LV apex. He is currently on aspirin 75mg and ticagrelor 90mg BD. No active bleeding. What is the most appropriate additional management?",
  options: { A:"No additional treatment — DAPT is sufficient", B:"Add warfarin (target INR 2–3) for 3–6 months", C:"Stop ticagrelor and switch to warfarin alone", D:"Add IV heparin infusion indefinitely", E:"Urgent surgical thrombectomy" },
  correct: "B",
  explanation: "Mural LV thrombus post-MI requires full anticoagulation (warfarin INR 2–3 or NOAC) for 3–6 months or until echo confirms resolution. DAPT alone is insufficient to prevent embolisation.",
  whyNot: {
    A:"DAPT alone does not adequately prevent stroke from LV thrombus.",
    C:"Stopping ticagrelor after recent STEMI/PCI risks stent thrombosis.",
    D:"IV heparin indefinitely is impractical; oral anticoagulation is standard.",
    E:"Surgical thrombectomy is not indicated for LV mural thrombus.",
  },
  tag: "Management",
},
// ── SECTION 7: SECONDARY PREVENTION ──────────────────────────────────────────
{
  section: "SECTION 7: SECONDARY PREVENTION",
  num: 31,
  stem: "A 58-year-old man had a STEMI and drug-eluting stent 3 months ago. He is on aspirin 75mg and ticagrelor 90mg BD. He develops upper GI bleeding. Endoscopy reveals a 1.5cm gastric ulcer; haemostasis is achieved. What is the most appropriate antiplatelet management post-haemostasis?",
  options: { A:"Stop both aspirin and ticagrelor immediately", B:"Stop ticagrelor only and continue aspirin alone", C:"Continue both aspirin and ticagrelor with addition of pantoprazole", D:"Switch to aspirin only for 1 month then resume DAPT", E:"Stop aspirin only and continue ticagrelor alone" },
  correct: "C",
  explanation: "After recent DES in ACS (<12 months), stopping DAPT risks catastrophic stent thrombosis. After haemostasis, DAPT should continue with pantoprazole added. GI bleeding risk is outweighed by stent thrombosis risk at 3 months.",
  whyNot: {
    A:"Stopping both agents at 3 months risks acute stent thrombosis (mortality ~50%).",
    B:"Aspirin monotherapy alone within 12 months post-DES/ACS carries unacceptably high ischaemic risk.",
    D:"Switching to aspirin only at 3 months is premature — minimum 12 months DAPT required.",
    E:"Continuing ticagrelor without aspirin is not guideline-endorsed.",
  },
  tag: "Management",
},
{
  section: null,
  num: 32,
  stem: "A 62-year-old man had a large anterior STEMI 6 weeks ago. Echo now shows EF 30%. He is in NYHA Class II heart failure on optimal medical therapy (ramipril + bisoprolol). What is the most appropriate additional intervention?",
  options: { A:"ICD implantation — EF ≤35% at any time post-MI warrants ICD", B:"Defer ICD assessment — it is too soon; reassess at 40 days post-MI", C:"ICD implantation — EF ≤35% at ≥40 days post-MI with NYHA Class II–III", D:"CRT — EF <35% always requires CRT first", E:"Prophylactic amiodarone instead of ICD" },
  correct: "C",
  explanation: "ICD is indicated when EF ≤35% persists at ≥40 days post-MI with NYHA Class II–III. At 6 weeks (42 days), this patient meets all three criteria.",
  whyNot: {
    A:"ICD must NOT be implanted in the first 40 days — EF may recover spontaneously.",
    B:"6 weeks = 42 days, beyond the 40-day threshold; ICD is now appropriate.",
    D:"CRT requires QRS ≥130ms (LBBB morphology) — no wide QRS mentioned.",
    E:"Prophylactic amiodarone does not reduce mortality post-MI and is not a substitute for ICD.",
  },
  tag: "Management",
},
{
  section: null,
  num: 33,
  stem: "A 69-year-old man post-STEMI is on atorvastatin 40mg. At 3-month review LDL is 2.1 mmol/L (target <1.4 mmol/L). He tolerates the statin well. What is the most appropriate next step?",
  options: { A:"Continue atorvastatin 40mg — LDL is close to target", B:"Switch to rosuvastatin 10mg", C:"Increase atorvastatin to 80mg", D:"Add fibrate therapy to atorvastatin 40mg", E:"Add omega-3 fatty acids to atorvastatin 40mg" },
  correct: "C",
  explanation: "ESC target LDL post-ACS is <1.4 mmol/L. This patient is above target on moderate-intensity statin. The next step is to maximise statin intensity — atorvastatin 80mg is the preferred high-intensity option.",
  whyNot: {
    A:"2.1 mmol/L is above the 1.4 mmol/L ESC target for high-risk patients.",
    B:"Switching statin class is not guideline-recommended first; maximise current statin.",
    D:"Fibrates primarily lower triglycerides, not LDL.",
    E:"Omega-3 fatty acids lower triglycerides, not LDL.",
  },
  tag: "Management",
},
{
  section: null,
  num: 34,
  stem: "A 65-year-old man who had an anterior STEMI 2 months ago is taking atorvastatin 80mg. Repeat LDL is 1.8 mmol/L (target <1.4 mmol/L). He is intolerant to dose escalation. What should be added next?",
  options: { A:"Fibrate (fenofibrate)", B:"Ezetimibe", C:"Colchicine", D:"Nicotinic acid", E:"Fish oil" },
  correct: "B",
  explanation: "When maximum-dose statin does not achieve target LDL, ezetimibe is the first adjunctive agent. It inhibits intestinal cholesterol absorption, reducing LDL by ~15–20%.",
  whyNot: {
    A:"Fibrates lower triglycerides primarily with limited LDL-lowering effect.",
    C:"Colchicine reduces cardiovascular events via anti-inflammatory mechanisms, not LDL lowering.",
    D:"Nicotinic acid is no longer recommended due to lack of outcome benefit.",
    E:"Fish oil lowers triglycerides, not LDL.",
  },
  tag: "Management",
},
// ── SECTION 8: STABLE ANGINA ──────────────────────────────────────────────────
{
  section: "SECTION 8: STABLE ANGINA",
  num: 35,
  stem: "A 56-year-old man with stable angina CCS Class II has a resting ECG showing LBBB. His cardiologist wishes to assess for inducible ischaemia. Which investigation is most appropriate?",
  options: { A:"Exercise tolerance test (ETT)", B:"Stress echocardiography", C:"CT coronary angiography", D:"Ambulatory (Holter) ECG monitoring", E:"Resting echocardiography" },
  correct: "B",
  explanation: "ETT is contraindicated in LBBB — baseline ST changes cause uninterpretable false positives. Stress echocardiography detects wall motion abnormalities independent of ECG and is the preferred imaging modality.",
  whyNot: {
    A:"ETT is contraindicated in LBBB due to false positive ST changes.",
    C:"CTCA provides anatomical (not functional) information — cannot assess ischaemia.",
    D:"Holter monitoring detects arrhythmias and dynamic ST changes but is not a stress modality.",
    E:"Resting echo cannot detect inducible ischaemia.",
  },
  tag: "Investigation",
},
{
  section: null,
  num: 36,
  stem: "A 61-year-old man with CCS Class III stable angina is on maximum medical therapy. Symptoms significantly limit his activities. Angiography shows single-vessel LAD disease with 80% stenosis. What is the most appropriate next step?",
  options: { A:"Add a second beta-blocker to increase heart rate control", B:"Refer for PCI for symptom relief", C:"Refer for CABG — single vessel disease always requires surgery", D:"Increase nitrate dose to overcome tolerance", E:"Add ranolazine as quadruple antianginal therapy" },
  correct: "B",
  explanation: "In stable angina, PCI does not reduce mortality vs OMT (COURAGE trial). However, PCI for symptom relief is a valid guideline-endorsed indication when symptoms are refractory to maximum medical therapy. Single-vessel LAD disease is manageable with PCI.",
  whyNot: {
    A:"Two beta-blockers are not combined — excessive bradycardia/heart block risk.",
    C:"CABG for single-vessel disease is generally reserved for left main stem or when PCI is not feasible.",
    D:"Increasing nitrate dose does not overcome tolerance; a nitrate-free window is required.",
    E:"Ranolazine is 4th/5th line; PCI for symptom control is more appropriate at this stage.",
  },
  tag: "Management",
},
{
  section: null,
  num: 37,
  stem: "A 54-year-old woman has three-vessel disease and type 2 diabetes (HbA1c 7.8%). Stress echo shows inducible wall motion abnormality in the inferior wall. SYNTAX score is 28. What is the most appropriate revascularisation strategy?",
  options: { A:"Medical management alone — stable symptoms do not require revascularisation", B:"PCI with drug-eluting stents — equivalent to CABG", C:"CABG — superior to PCI in diabetics with multivessel disease", D:"PCI is preferred due to intermediate SYNTAX score", E:"PCI with rotational atherectomy for calcified lesions" },
  correct: "C",
  explanation: "The FREEDOM trial demonstrated CABG is superior to PCI in diabetics with multivessel disease — lower rates of MI and mortality at 5 years. A SYNTAX score of 28 (intermediate) with DM further strengthens the CABG recommendation.",
  whyNot: {
    A:"Significant symptomatic multivessel disease with inducible ischaemia in a diabetic warrants revascularisation.",
    B:"FREEDOM trial specifically showed PCI is inferior to CABG in this population.",
    D:"SYNTAX 28 in a diabetic patient favours CABG; low SYNTAX (<23) is where PCI and CABG are more equivalent.",
    E:"Rotational atherectomy is a technique for calcified lesions — not a revascularisation strategy choice.",
  },
  tag: "Management",
},
// ── SECTION 9: DRUG TRAPS & CONTRAINDICATIONS ─────────────────────────────────
{
  section: "SECTION 9: DRUG TRAPS & CONTRAINDICATIONS",
  num: 38,
  stem: "A 58-year-old man with a history of TIA 4 months ago presents with STEMI. Primary PCI is planned. Which P2Y12 inhibitor is contraindicated?",
  options: { A:"Ticagrelor", B:"Clopidogrel", C:"Prasugrel", D:"All P2Y12 inhibitors are contraindicated", E:"Ticagrelor and clopidogrel, but not prasugrel" },
  correct: "C",
  explanation: "Prasugrel is contraindicated in patients with prior TIA or stroke due to significantly increased intracranial haemorrhage risk. Ticagrelor and clopidogrel are both acceptable.",
  whyNot: {
    A:"Ticagrelor is safe and preferred in this patient.",
    B:"Clopidogrel is safe in patients with prior TIA/stroke.",
    D:"Only prasugrel is contraindicated; the other P2Y12 inhibitors are appropriate.",
    E:"This is the opposite — only prasugrel is contraindicated.",
  },
  tag: "Contraindication",
},
{
  section: null,
  num: 39,
  stem: "A 47-year-old woman with new LBBB and chest pain reports taking tadalafil 36 hours ago. BP 168/102 mmHg. She has severe chest pain. Which medication is safe to give for pain relief?",
  options: { A:"GTN sublingual 400 mcg", B:"GTN IV infusion at 10 mcg/min", C:"IV morphine 2.5mg", D:"Isosorbide dinitrate sublingual", E:"Oral nicorandil" },
  correct: "C",
  explanation: "GTN and all nitrates are contraindicated within 48 hours of tadalafil (long-acting PDE-5 inhibitor). IV morphine remains an option for pain relief, used cautiously given its interaction with antiplatelet absorption.",
  whyNot: {
    A:"GTN sublingual is a nitrate — contraindicated within 48h of tadalafil.",
    B:"GTN IV is a nitrate — same 48-hour contraindication.",
    D:"Isosorbide dinitrate is a nitrate — same contraindication.",
    E:"Nicorandil is a nitrate-like potassium channel opener releasing NO — same risk.",
  },
  tag: "Contraindication",
},
{
  section: null,
  num: 40,
  stem: "A 72-year-old man with anterior STEMI is haemodynamically unstable (BP 76/48 mmHg, cardiogenic shock) with acute pulmonary oedema. Which medication should be withheld at this time?",
  options: { A:"IV furosemide", B:"IV noradrenaline", C:"Oral metoprolol", D:"Aspirin", E:"Unfractionated heparin" },
  correct: "C",
  explanation: "Beta-blockers are absolutely contraindicated in acute cardiogenic shock and acute pulmonary oedema post-MI. They reduce cardiac output — potentially fatal in a shocked patient. Start only when haemodynamically stable.",
  whyNot: {
    A:"Furosemide is appropriate for acute pulmonary oedema (reduces preload).",
    B:"Noradrenaline is appropriate in cardiogenic shock to maintain perfusion pressure.",
    D:"Aspirin is indicated and has no haemodynamic effects.",
    E:"UFH anticoagulation is appropriate in STEMI with cardiogenic shock.",
  },
  tag: "Contraindication",
},
{
  section: null,
  num: 41,
  stem: "A 52-year-old man with inferior STEMI received thrombolysis 45 minutes ago. ECG shows a wide-complex rhythm at 78 bpm, regular, with no discernible P waves. He is alert, BP 116/74 mmHg, and chest pain has resolved. What is the most appropriate action?",
  options: { A:"Immediate DC cardioversion at 200J", B:"IV amiodarone 300mg bolus", C:"Continue monitoring — this is a reperfusion arrhythmia requiring no treatment", D:"IV lignocaine 1mg/kg bolus", E:"Urgent rescue PCI — thrombolysis has failed" },
  correct: "C",
  explanation: "AIVR — wide-complex rhythm at 60–120 bpm with no P waves — is a hallmark of successful reperfusion. Chest pain resolved and haemodynamic stability confirm success. No treatment is required.",
  whyNot: {
    A:"AIVR is not VT — it does not cause haemodynamic compromise.",
    B:"Amiodarone is not indicated for AIVR.",
    D:"Lignocaine is not indicated for AIVR.",
    E:"Successful thrombolysis criteria are met (pain resolved, stable); rescue PCI is for failed thrombolysis.",
  },
  tag: "Emergency",
},
// ── SECTION 10: SPECIAL SCENARIOS ────────────────────────────────────────────
{
  section: "SECTION 10: SPECIAL SCENARIOS",
  num: 42,
  stem: "A 38-year-old woman, 6 weeks postpartum, presents with sudden chest pain and dyspnoea. ECG shows ST elevation in V1–V4. Troponin is elevated. She has no cardiovascular risk factors. Coronary angiography reveals no atherosclerotic plaques but shows a linear filling defect in the LAD with a false lumen. What is the most likely diagnosis?",
  options: { A:"Type 1 MI from plaque rupture", B:"Spontaneous coronary artery dissection (SCAD)", C:"Coronary artery spasm (Prinzmetal angina)", D:"Cocaine-induced MI", E:"Takotsubo cardiomyopathy" },
  correct: "B",
  explanation: "SCAD most commonly affects young women in the peripartum period. It presents as STEMI/NSTEMI with no atherosclerotic risk factors. Angiography shows a linear filling defect (false lumen) or smooth tapering without plaque.",
  whyNot: {
    A:"Type 1 MI requires atherosclerotic plaque — none present here.",
    C:"Vasospasm would cause smooth coronary arteries without a filling defect.",
    D:"No cocaine history; no vasospasm pattern.",
    E:"Takotsubo presents with apical ballooning and T-wave inversion; no coronary dissection.",
  },
  tag: "Diagnosis",
},
{
  section: null,
  num: 43,
  stem: "A 44-year-old male cocaine user presents with 1 hour of chest pain and BP 186/104 mmHg. ECG shows ST elevation in V1–V4. Which medication is contraindicated and should be avoided?",
  options: { A:"GTN sublingual", B:"Aspirin 300mg", C:"Intravenous propranolol", D:"IV diazepam", E:"IV lorazepam" },
  correct: "C",
  explanation: "Beta-blockers are contraindicated in cocaine-induced MI. Cocaine causes alpha-adrenergic vasoconstriction; beta-blockade removes competing beta-vasodilation, resulting in unopposed alpha stimulation — worsening coronary vasospasm and hypertension.",
  whyNot: {
    A:"GTN causes coronary vasodilation — appropriate to counter cocaine-induced spasm.",
    B:"Aspirin is appropriate for its antiplatelet effect.",
    D:"Benzodiazepines are first-line in cocaine toxicity — they reduce sympathetic overactivity.",
    E:"Lorazepam is a benzodiazepine and is appropriate.",
  },
  tag: "Contraindication",
},
{
  section: null,
  num: 44,
  stem: "A 75-year-old woman (weight 52kg) with CKD (eGFR 28 mL/min) and recent large anterior STEMI requires DAPT choice. Which P2Y12 inhibitor combined with aspirin should be prescribed?",
  options: { A:"Prasugrel 10mg OD", B:"Prasugrel 5mg OD (reduced dose)", C:"Ticagrelor 90mg BD", D:"Clopidogrel 75mg OD", E:"Prasugrel 60mg loading then 10mg OD" },
  correct: "D",
  explanation: "Prasugrel is contraindicated: age >75 AND weight <60kg AND CKD — all three present. In this very high bleeding-risk scenario, clopidogrel 75mg OD is the safest P2Y12 option.",
  whyNot: {
    A:"Prasugrel 10mg OD — absolutely contraindicated (age >75, weight <60kg).",
    B:"Even reduced-dose prasugrel is not recommended in patients aged >75 with weight <60kg.",
    C:"Ticagrelor is acceptable over prasugrel but clopidogrel is the safest choice in the highest bleeding-risk patient.",
    E:"Full-dose prasugrel is the highest bleeding-risk option and absolutely contraindicated.",
  },
  tag: "Contraindication",
},
{
  section: null,
  num: 45,
  stem: "A 63-year-old man has just had a drug-eluting stent for NSTEMI. Before discharge he asks which medication he must never miss. He is on aspirin 75mg, ticagrelor 90mg BD, ramipril, bisoprolol, atorvastatin 80mg, and pantoprazole. Which single medication, if stopped abruptly, carries the highest immediate risk of death?",
  options: { A:"Ramipril", B:"Bisoprolol", C:"Atorvastatin", D:"Ticagrelor", E:"Pantoprazole" },
  correct: "D",
  explanation: "Stopping ticagrelor (or any P2Y12 inhibitor) abruptly within 12 months of drug-eluting stent insertion risks acute in-stent thrombosis — a catastrophic event with approximately 50% mortality.",
  whyNot: {
    A:"Stopping ramipril causes blood pressure rise but not stent thrombosis.",
    B:"Stopping bisoprolol causes rebound tachycardia — risky but not as immediately lethal.",
    C:"Stopping atorvastatin increases long-term risk but does not cause an acute event.",
    E:"Stopping pantoprazole increases GI bleeding risk but not an acute cardiovascular event.",
  },
  tag: "Management",
},
// ── SECTION 11: INVESTIGATIONS & SCORING ─────────────────────────────────────
{
  section: "SECTION 11: INVESTIGATIONS & SCORING",
  num: 46,
  stem: "A 67-year-old man with NSTEMI has a GRACE score calculated. He is haemodynamically stable with ST deviation, elevated markers, Killip Class I, no cardiac arrest, creatinine 110 µmol/L, HR 95 bpm, and SBP 138 mmHg. What GRACE risk category does this patient fall into?",
  options: { A:"Low risk — GRACE <109", B:"Intermediate risk — GRACE 109–140", C:"High risk — GRACE >140", D:"Cannot be determined without echocardiography", E:"Cannot be determined without angiography" },
  correct: "B",
  explanation: "This profile — moderately elevated age, mild tachycardia, near-normal BP, near-normal creatinine, Killip I, no cardiac arrest, with ST deviation and elevated markers — typically corresponds to an intermediate GRACE score (109–140), warranting early invasive strategy within 24–72 hours.",
  whyNot: {
    A:"Low risk would require younger age, lower HR, no ECG changes, normal markers.",
    C:"High risk (>140) typically involves older age, higher creatinine, higher Killip class, or cardiac arrest.",
    D:"Echo is not part of the GRACE score inputs.",
    E:"Angiography is not part of the GRACE score inputs.",
  },
  tag: "CutOff",
},
{
  section: null,
  num: 47,
  stem: "A 55-year-old man with anterior STEMI received thrombolysis at the referring hospital before transfer. At 90 minutes post-thrombolysis, his ECG shows ST elevation in V1–V4 has decreased from 6mm to 2.5mm. Chest pain has resolved. What is the correct interpretation?",
  options: { A:"Reperfusion failed — ST elevation should be fully resolved", B:"ST elevation reduced by less than 50% — rescue PCI required", C:"ST elevation reduced by 58% — consistent with successful reperfusion", D:"Persistent ST elevation indicates LV aneurysm formation", E:"ST resolution is irrelevant — only troponin matters for reperfusion assessment" },
  correct: "C",
  explanation: "Successful reperfusion = ≥50% reduction in ST elevation at 90 minutes. Here: (6–2.5)/6 = 58% reduction — exceeds the 50% threshold. Combined with pain resolution this confirms successful reperfusion.",
  whyNot: {
    A:"50% reduction is the threshold for success; full resolution is not required.",
    B:"58% reduction IS ≥50% — rescue PCI is not needed.",
    D:"LV aneurysm develops over weeks to months, not within 90 minutes of MI.",
    E:"ST resolution is a validated primary marker for reperfusion assessment.",
  },
  tag: "Interpretation",
},
// ── SECTION 12: COMPLICATIONS TIMING ─────────────────────────────────────────
{
  section: "SECTION 12: COMPLICATIONS TIMING",
  num: 48,
  stem: "A 68-year-old man had a large inferior STEMI 3 days ago treated with primary PCI. He is haemodynamically stable. Which complication is he currently at HIGHEST risk of developing over the next 4 days?",
  options: { A:"Primary ventricular fibrillation", B:"Cardiogenic shock from extensive LV damage", C:"Dressler's syndrome", D:"Free wall rupture or VSD", E:"LV aneurysm formation" },
  correct: "D",
  explanation: "Mechanical complications (free wall rupture, VSD, papillary rupture) peak at 3–7 days post-MI due to macrophage-mediated softening of the necrotic myocardium. At day 3, he is entering the peak risk window.",
  whyNot: {
    A:"Primary VF peaks within the first 4 hours; by day 3 this risk is markedly reduced.",
    B:"Cardiogenic shock from pump failure presents in the first 24–48 hours; by day 3 in a stable patient this risk has largely passed.",
    C:"Dressler's syndrome occurs at 2–10 weeks post-MI.",
    E:"LV aneurysm develops over weeks to months as fibrotic scar matures.",
  },
  tag: "Timing",
},
{
  section: null,
  num: 49,
  stem: "A 71-year-old man develops fever, leukocytosis, pleuritic chest pain, and pericardial friction rub on day 2 post-anterior STEMI. Troponin has been declining from a peak of 8.2 ng/mL. ECG shows localised ST changes in the infarct territory. What is the most likely diagnosis?",
  options: { A:"Dressler's syndrome", B:"Reinfarction", C:"Early post-MI pericarditis (epistenocardiac pericarditis)", D:"Aortic dissection as the original event", E:"Infective endocarditis" },
  correct: "C",
  explanation: "Pericardial friction rub, pleuritic chest pain, and fever within 1–3 days of transmural MI = early post-MI pericarditis. Troponin is declining (not rising), excluding reinfarction.",
  whyNot: {
    A:"Dressler's syndrome occurs 2–10 weeks post-MI, not on day 2.",
    B:"Reinfarction requires a new troponin rise; troponin is declining.",
    D:"Aortic dissection would not cause a friction rub on day 2 of an STEMI admission.",
    E:"Infective endocarditis does not cause localised infarct-territory ECG changes in this context.",
  },
  tag: "Timing",
},
{
  section: null,
  num: 50,
  stem: "A 66-year-old woman presents to her GP 5 weeks after a large anterior STEMI with recurrent chest pain, temperature 38.5°C, WBC 14×10⁹/L, and ESR 82 mm/hr. Troponin is negative. CXR shows cardiomegaly and a small left-sided pleural effusion. Echo shows a small-moderate pericardial effusion. What is the most appropriate treatment?",
  options: { A:"Prednisolone 1mg/kg/day — autoimmune condition", B:"Aspirin plus colchicine", C:"Intravenous antibiotics — fever and leukocytosis suggest infection", D:"Immediate coronary angiography — possible reinfarction", E:"Aspirin only — she is already on aspirin post-MI" },
  correct: "B",
  explanation: "Classic Dressler's syndrome at 5 weeks post-MI: fever, elevated ESR, negative troponin, pericardial + pleural effusion. First-line: NSAIDs (aspirin or ibuprofen) PLUS colchicine. At 5 weeks infarct is healed so NSAIDs are safe.",
  whyNot: {
    A:"Corticosteroids are reserved for refractory Dressler's failing NSAIDs + colchicine.",
    C:"This is autoimmune pericarditis, not bacterial infection.",
    D:"Negative troponin excludes reinfarction.",
    E:"Aspirin alone without colchicine has higher recurrence rate; colchicine is essential.",
  },
  tag: "Management",
},
];

// ── VARIATION QUESTIONS ───────────────────────────────────────────────────────
const variations = [
{
  section: "VARIATIONS ON QUESTION 23: Post-MI Mechanical Complication Differentiation",
  varNum: 1,
  stem: "A 63-year-old man is day 5 post-anterior STEMI. He develops sudden dyspnoea and haemodynamic collapse. A new pansystolic murmur is heard at the left lower sternal border. Swan-Ganz data: RA O2 sat 65%, RV O2 sat 78%, PA O2 sat 79%, PCWP 24 mmHg. What is the diagnosis?",
  options: { A:"Acute mitral regurgitation from papillary muscle rupture", B:"Left ventricular free wall rupture", C:"Post-MI ventricular septal defect", D:"Right ventricular infarction", E:"Acute aortic regurgitation" },
  correct: "C",
  explanation: "O2 saturation step-up from RA (65%) to RV (78%) of 13% — far exceeding the 8% threshold — confirms a left-to-right intracardiac shunt = VSD.",
  whyNot: {
    A:"Acute MR shows large V waves on PCWP without an O2 step-up.",
    B:"Free wall rupture causes tamponade — RA, RV, and PCWP equalise; no O2 step-up.",
    D:"RV infarction causes hypotension with raised JVP but no O2 step-up.",
    E:"Aortic regurgitation causes a diastolic murmur and no haemodynamic shunt.",
  },
  tag: "Diagnosis",
},
{
  section: null,
  varNum: 2,
  stem: "A 69-year-old woman develops acute pulmonary oedema on day 4 post-inferior STEMI. A new holosystolic murmur is heard loudest at the cardiac apex. Right heart catheterisation: RA O2 sat 64%, RV O2 sat 65%, PCWP 32 mmHg with giant V waves. What is the diagnosis?",
  options: { A:"Post-MI ventricular septal defect", B:"Left ventricular free wall rupture with subacute tamponade", C:"Post-MI acute mitral regurgitation", D:"Stress cardiomyopathy (Takotsubo)", E:"Aortic stenosis decompensation" },
  correct: "C",
  explanation: "Giant V waves on PCWP indicate systolic backflow into the LA = acute MR. No O2 step-up from RA to RV (64% vs 65%) excludes VSD. Inferior MI + apical murmur = posterior papillary muscle rupture.",
  whyNot: {
    A:"VSD requires O2 step-up RA→RV; absent here.",
    B:"Free wall rupture causes haemopericardium and tamponade physiology, not giant V waves.",
    D:"Takotsubo is not a mechanical rupture complication.",
    E:"Aortic stenosis causes a systolic ejection murmur at the base, not an acute new murmur post-MI.",
  },
  tag: "Diagnosis",
},
{
  section: null,
  varNum: 3,
  stem: "A 71-year-old man is day 6 post-anterior STEMI. He suddenly loses consciousness. CPR is commenced. ECG shows organised electrical activity. Bedside echo reveals a large pericardial effusion with right heart diastolic collapse. No new murmur was heard before arrest. What is the diagnosis?",
  options: { A:"Post-MI ventricular septal defect", B:"Cardiogenic shock from LV failure", C:"Left ventricular free wall rupture with tamponade", D:"Post-MI acute mitral regurgitation", E:"Stress-induced ventricular fibrillation" },
  correct: "C",
  explanation: "PEA + day 6 post-MI + pericardial effusion with diastolic right heart collapse = free wall rupture causing haemopericardium and tamponade. Absence of murmur differentiates this from VSD or MR.",
  whyNot: {
    A:"VSD causes a loud holosystolic murmur at the left sternal border; no effusion.",
    B:"Cardiogenic shock from LV failure shows pulmonary oedema, not pericardial effusion.",
    D:"Acute MR causes a loud apical murmur; no pericardial effusion.",
    E:"VF is a shockable rhythm; this patient has PEA (organised electrical activity).",
  },
  tag: "Diagnosis",
},
{
  section: null,
  varNum: 4,
  stem: "A 64-year-old woman develops a new loud systolic murmur and flash pulmonary oedema on day 5 post-MI. Both post-MI VSD and post-MI MR are being considered. Which Swan-Ganz finding would MOST specifically point towards VSD rather than MR?",
  options: { A:"Low cardiac output (1.9 L/min)", B:"PCWP 28 mmHg", C:"Oxygen saturation step-up of 10% from right atrium to right ventricle", D:"Giant V waves on the PCWP tracing", E:"Systemic hypotension (BP 80/50 mmHg)" },
  correct: "C",
  explanation: "An O2 step-up of ≥8% from RA to RV is pathognomonic of a left-to-right intracardiac shunt at the ventricular level = VSD.",
  whyNot: {
    A:"Low cardiac output occurs in both VSD and MR — non-specific.",
    B:"Elevated PCWP occurs in both conditions — non-specific.",
    D:"Giant V waves are specific for MR, not VSD.",
    E:"Hypotension occurs in both mechanical complications — non-specific.",
  },
  tag: "Investigation",
},
{
  section: null,
  varNum: 5,
  stem: "A 67-year-old man is day 4 post-inferior STEMI. A new holosystolic murmur is noted. BP is 96/60 mmHg. You are uncertain whether this is post-MI VSD or acute MR. Which bedside investigation is the FASTEST and MOST accurate way to differentiate them?",
  options: { A:"Right heart catheterisation (Swan-Ganz)", B:"Chest X-ray", C:"12-lead ECG", D:"Bedside transthoracic echocardiography with colour flow Doppler", E:"Arterial blood gas" },
  correct: "D",
  explanation: "Bedside echo with colour flow Doppler is the fastest, non-invasive tool to distinguish VSD (septal defect with L→R jet) from acute MR (flail leaflet, regurgitant jet). It should be performed first.",
  whyNot: {
    A:"Swan-Ganz is the most specific haemodynamic test but is invasive and time-consuming; echo comes first.",
    B:"CXR shows pulmonary oedema but cannot distinguish VSD from MR.",
    C:"ECG shows MI territory but cannot diagnose mechanical complications.",
    E:"ABG shows hypoxia from pulmonary oedema — no diagnostic specificity for VSD vs MR.",
  },
  tag: "NextBestStep",
},
];

// ═══════════════════════════════════════════════════════════════════════════════
// DOCUMENT ASSEMBLY
// ═══════════════════════════════════════════════════════════════════════════════
const children = [];

// Cover page
children.push(new Paragraph({
  alignment: AlignmentType.CENTER,
  spacing: { before: 1440, after: 480 },
  children: [new TextRun({ text: "HKMLE MODULE 1A", bold: true, size: 56, color: TEAL })],
}));
children.push(new Paragraph({
  alignment: AlignmentType.CENTER,
  spacing: { before: 0, after: 240 },
  children: [new TextRun({ text: "ACUTE CORONARY SYNDROME", bold: true, size: 40, color: TEAL })],
}));
children.push(new Paragraph({
  alignment: AlignmentType.CENTER,
  spacing: { before: 0, after: 240 },
  children: [new TextRun({ text: "Single Best Answer MCQs", bold: true, size: 32, color: "555555" })],
}));
children.push(new Paragraph({
  alignment: AlignmentType.CENTER,
  spacing: { before: 0, after: 120 },
  children: [new TextRun({ text: "50 Questions + 5 Variations | All High-Yield Concepts", size: 24, color: "777777" })],
}));
children.push(new Paragraph({
  alignment: AlignmentType.CENTER,
  spacing: { before: 0, after: 1440 },
  children: [new TextRun({ text: "July 2026", italics: true, size: 22, color: "888888" })],
}));
children.push(new Paragraph({ children: [new PageBreak()] }));

// Questions
let lastSection = "";
for (const q of questions) {
  if (q.section && q.section !== lastSection) {
    children.push(heading1(q.section));
    lastSection = q.section;
  }
  children.push(heading2(`Question ${q.num}`));
  children.push(shadedPara(q.stem, GREY));
  children.push(plain(""));

  const optLetters = ["A", "B", "C", "D", "E"];
  for (const l of optLetters) {
    children.push(optionPara(l, q.options[l], l === q.correct));
  }
  children.push(plain(""));
  children.push(answerBox(q.correct, q.explanation));

  const wrongLetters = optLetters.filter(l => l !== q.correct);
  for (const l of wrongLetters) {
    children.push(whyNotLine(l, q.whyNot[l]));
  }
  children.push(tagLine(q.tag));
  children.push(divider());
}

// Variations header
children.push(new Paragraph({ children: [new PageBreak()] }));
children.push(heading1("⭐ HARDEST QUESTION IDENTIFIED"));
children.push(plain("Question 23 (Swan-Ganz VSD vs MR differentiation) is the most complex — requiring integration of haemodynamic data, ECG territory, physical exam, and anatomy simultaneously. Below are 5 variations testing the same concept.", false, 20));
children.push(plain(""));

let lastVarSection = "";
for (const v of variations) {
  if (v.section && v.section !== lastVarSection) {
    children.push(heading1(v.section));
    lastVarSection = v.section;
  }
  children.push(heading2(`Variation ${v.varNum}`));
  children.push(shadedPara(v.stem, GREY));
  children.push(plain(""));

  const optLetters = ["A", "B", "C", "D", "E"];
  for (const l of optLetters) {
    children.push(optionPara(l, v.options[l], l === v.correct));
  }
  children.push(plain(""));
  children.push(answerBox(v.correct, v.explanation));

  const wrongLetters = optLetters.filter(l => l !== v.correct);
  for (const l of wrongLetters) {
    children.push(whyNotLine(l, v.whyNot[l]));
  }
  children.push(tagLine(v.tag));
  children.push(divider());
}

// Build doc
const doc = new Document({
  creator: "HKMLE Tutor",
  title: "HKMLE Module 1A ACS MCQs",
  description: "50 HKMLE-style Single Best Answer MCQs on Acute Coronary Syndrome",
  sections: [{ children }],
});

Packer.toBuffer(doc).then(buffer => {
  fs.writeFileSync("/home/daytona/workspace/hkmle-acs/HKMLE_Module1A_ACS_MCQs.docx", buffer);
  console.log("SUCCESS: file written");
}).catch(err => {
  console.error("ERROR:", err.message);
});

cd /home/daytona/workspace/hkmle-acs && node mcq_generator.js 2>&1

ls -lh /home/daytona/workspace/hkmle-acs/HKMLE_Module1A_ACS_MCQs.docx

cd /home/daytona/workspace/hkmle-acs && python3 -c " from docx import Document d…

cd /home/daytona/workspace/hkmle-acs && node -e " const { Document } = require('…

which libreoffice && libreoffice --version 2>/dev/null; which pandoc && pandoc -…

cd /home/daytona/workspace/hkmle-acs && libreoffice --headless --convert-to pdf …

cp /home/daytona/workspace/hkmle-acs/HKMLE_Module1A_ACS_MCQs.docx /tmp/mcq_conve…

cp /tmp/mcq_convert.pdf /home/daytona/workspace/hkmle-acs/HKMLE_Module1A_ACS_MCQ…